https://trial.medpath.com/news/esperare-secures-gates-foundation-grant-to-develop-novel-preeclampsia-therapy 2025-12-04T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esperare-secures-gates-foundation-grant-to-develop-novel-preeclampsia-therapy 2025-12-04T17:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/bioage-labs-reports-positive-phase-1-data-for-brain-penetrant-nlrp3-inhibitor-bge-102 2025-12-04T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioage-labs-reports-positive-phase-1-data-for-brain-penetrant-nlrp3-inhibitor-bge-102 2025-12-04T17:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/j-d-pharmaceuticals-receives-fda-orphan-drug-designation-for-hepatocellular-carcinoma-treatment 2025-12-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-d-pharmaceuticals-receives-fda-orphan-drug-designation-for-hepatocellular-carcinoma-treatment 2025-12-04T17:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/bd-and-chemoglo-partner-to-enhance-hazardous-drug-contamination-testing-in-healthcare-facilities 2025-12-04T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-and-chemoglo-partner-to-enhance-hazardous-drug-contamination-testing-in-healthcare-facilities 2025-12-04T17:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/merakris-therapeutics-achieves-fda-alignment-on-mtx-001-development-pathway-for-chronic-venous-leg-ulcers 2025-12-04T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merakris-therapeutics-achieves-fda-alignment-on-mtx-001-development-pathway-for-chronic-venous-leg-ulcers 2025-12-04T17:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/italian-no-cut-trial-shows-nonoperative-management-safe-for-rectal-cancer-patients-after-complete-response 2025-12-04T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/italian-no-cut-trial-shows-nonoperative-management-safe-for-rectal-cancer-patients-after-complete-response 2025-12-04T17:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/microbiota-therapy-maat013-achieves-62-response-rate-in-refractory-gi-agvhd-phase-3-trial 2025-12-04T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiota-therapy-maat013-achieves-62-response-rate-in-refractory-gi-agvhd-phase-3-trial 2025-12-04T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-higher-user-fees-for-overseas-phase-i-trials-to-boost-domestic-drug-development 2025-12-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-higher-user-fees-for-overseas-phase-i-trials-to-boost-domestic-drug-development 2025-12-04T17:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/malawi-becomes-fourth-african-nation-to-approve-lenacapavir-gilead-s-twice-yearly-hiv-prevention-injectable 2025-12-04T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malawi-becomes-fourth-african-nation-to-approve-lenacapavir-gilead-s-twice-yearly-hiv-prevention-injectable 2025-12-04T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/hope-medicine-s-hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment 2025-12-04T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-medicine-s-hmi-115-receives-fda-fast-track-designation-for-endometriosis-pain-treatment 2025-12-04T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-health-secures-78-million-series-b-to-expand-ai-powered-clinical-trial-platform-across-us-healthcare-systems 2025-12-04T17:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-health-secures-78-million-series-b-to-expand-ai-powered-clinical-trial-platform-across-us-healthcare-systems 2025-12-04T17:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/terasaki-institute-develops-organ-on-chip-platform-to-test-cancer-vaccines-in-aging-populations 2025-12-04T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terasaki-institute-develops-organ-on-chip-platform-to-test-cancer-vaccines-in-aging-populations 2025-12-04T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-glp-1-obesity-drugs-set-to-transform-korean-market-as-eli-lilly-and-novo-nordisk-advance-next-generation-therapies 2025-12-04T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-glp-1-obesity-drugs-set-to-transform-korean-market-as-eli-lilly-and-novo-nordisk-advance-next-generation-therapies 2025-12-04T13:31:30+00:00 hourly 0.9 https://trial.medpath.com/news/brazil-approves-world-s-first-single-dose-dengue-vaccine-following-severe-2024-outbreak 2025-12-04T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazil-approves-world-s-first-single-dose-dengue-vaccine-following-severe-2024-outbreak 2025-12-04T13:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-secures-275-million-royalty-deal-with-royalty-pharma-for-hunter-syndrome-therapy 2025-12-04T13:30:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-secures-275-million-royalty-deal-with-royalty-pharma-for-hunter-syndrome-therapy 2025-12-04T13:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/labgenius-and-sanofi-expand-ai-driven-antibody-partnership-with-new-nanobody-optimization-collaboration 2025-12-04T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labgenius-and-sanofi-expand-ai-driven-antibody-partnership-with-new-nanobody-optimization-collaboration 2025-12-04T13:30:36+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-and-crescent-biopharma-form-strategic-partnership-to-advance-novel-oncology-therapeutics 2025-12-04T13:30:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-and-crescent-biopharma-form-strategic-partnership-to-advance-novel-oncology-therapeutics 2025-12-04T13:30:31+00:00 hourly 0.9 https://trial.medpath.com/news/formycon-partners-with-ms-pharma-for-keytruda-biosimilar-fyb206-commercialization-in-mena-region 2025-12-04T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formycon-partners-with-ms-pharma-for-keytruda-biosimilar-fyb206-commercialization-in-mena-region 2025-12-04T13:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/mabxience-and-hp-develop-ai-powered-digital-twin-for-monoclonal-antibody-manufacturing 2025-12-04T13:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabxience-and-hp-develop-ai-powered-digital-twin-for-monoclonal-antibody-manufacturing 2025-12-04T13:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-partners-with-aws-to-launch-agentic-ai-platform-for-clinical-trial-automation 2025-12-04T13:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-partners-with-aws-to-launch-agentic-ai-platform-for-clinical-trial-automation 2025-12-04T13:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-significantly-improves-quality-of-life-in-chronic-spontaneous-urticaria-patients 2025-12-04T13:29:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-significantly-improves-quality-of-life-in-chronic-spontaneous-urticaria-patients 2025-12-04T13:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-completes-acquisition-of-vicebio-expanding-respiratory-vaccine-portfolio-with-molecular-clamp-technology 2025-12-04T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-completes-acquisition-of-vicebio-expanding-respiratory-vaccine-portfolio-with-molecular-clamp-technology 2025-12-04T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-begins-first-in-human-trial-of-lassa-fever-vaccine-using-covid-19-platform-technology 2025-12-04T13:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-begins-first-in-human-trial-of-lassa-fever-vaccine-using-covid-19-platform-technology 2025-12-04T13:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/laigo-bio-secures-eur11-5-million-to-advance-novel-protein-degradation-platform-for-cancer-and-autoimmune-diseases 2025-12-04T13:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/laigo-bio-secures-eur11-5-million-to-advance-novel-protein-degradation-platform-for-cancer-and-autoimmune-diseases 2025-12-04T13:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/actithera-appoints-radiopharmaceutical-veteran-dr-darshan-dalal-as-chief-medical-officer-to-lead-fap-targeting-therapy-development 2025-12-04T13:27:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actithera-appoints-radiopharmaceutical-veteran-dr-darshan-dalal-as-chief-medical-officer-to-lead-fap-targeting-therapy-development 2025-12-04T13:27:46+00:00 hourly 0.9 https://trial.medpath.com/news/monte-rosa-therapeutics-reports-promising-mrt-8102-cardiovascular-data-and-prepares-updated-mrt-2359-cancer-results 2025-12-04T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monte-rosa-therapeutics-reports-promising-mrt-8102-cardiovascular-data-and-prepares-updated-mrt-2359-cancer-results 2025-12-04T13:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-valorum-biologics-for-us-launch-of-cancer-biosimilar-armlupeg 2025-12-04T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-partners-with-valorum-biologics-for-us-launch-of-cancer-biosimilar-armlupeg 2025-12-04T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-initiates-phase-iia-trial-for-novel-alport-syndrome-treatment-bay-3401016 2025-12-04T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-initiates-phase-iia-trial-for-novel-alport-syndrome-treatment-bay-3401016 2025-12-04T13:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/ionctura-initiates-phase-i-ii-trial-combining-roginolisib-with-ruxolitinib-for-jak-inhibitor-resistant-myelofibrosis 2025-12-04T13:26:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionctura-initiates-phase-i-ii-trial-combining-roginolisib-with-ruxolitinib-for-jak-inhibitor-resistant-myelofibrosis 2025-12-04T13:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/garsorasib-shows-45-5-response-rate-in-kras-g12c-mutated-pancreatic-cancer-patients 2025-12-04T13:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/garsorasib-shows-45-5-response-rate-in-kras-g12c-mutated-pancreatic-cancer-patients 2025-12-04T13:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/avencell-therapeutics-receives-fda-and-ema-clearance-for-phase-i-ii-trial-of-dual-target-allogeneic-car-t-therapy 2025-12-04T13:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avencell-therapeutics-receives-fda-and-ema-clearance-for-phase-i-ii-trial-of-dual-target-allogeneic-car-t-therapy 2025-12-04T13:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-announces-shift-to-single-trial-standard-for-drug-approvals-under-new-commissioner-makary 2025-12-04T13:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-announces-shift-to-single-trial-standard-for-drug-approvals-under-new-commissioner-makary 2025-12-04T13:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/atavistik-bio-unveils-novel-jak2-v617f-mutant-selective-inhibitors-for-myeloproliferative-neoplasms-at-ash-2025 2025-12-04T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atavistik-bio-unveils-novel-jak2-v617f-mutant-selective-inhibitors-for-myeloproliferative-neoplasms-at-ash-2025 2025-12-04T12:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-raises-295-million-in-hong-kong-ipo-as-ai-drug-discovery-gains-momentum 2025-12-04T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-raises-295-million-in-hong-kong-ipo-as-ai-drug-discovery-gains-momentum 2025-12-04T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advances-new-approach-methodologies-to-reduce-animal-testing-in-drug-development 2025-12-04T10:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advances-new-approach-methodologies-to-reduce-animal-testing-in-drug-development 2025-12-04T10:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/cms-proposes-major-medicare-advantage-and-part-d-reforms-for-2027-streamlining-star-ratings-and-drug-coverage-programs 2025-12-04T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-proposes-major-medicare-advantage-and-part-d-reforms-for-2027-streamlining-star-ratings-and-drug-coverage-programs 2025-12-04T09:26:55+00:00 hourly 0.9 https://trial.medpath.com/news/former-fda-and-cdc-leaders-warn-against-proposed-vaccine-policy-changes-amid-acip-deliberations 2025-12-04T09:26:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-fda-and-cdc-leaders-warn-against-proposed-vaccine-policy-changes-amid-acip-deliberations 2025-12-04T09:26:28+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-of-appeal-upholds-trademark-injunction-against-samsung-bioepis-byooviz-biosimilar 2025-12-04T09:25:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-of-appeal-upholds-trademark-injunction-against-samsung-bioepis-byooviz-biosimilar 2025-12-04T09:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/hiropharmaconsulting-receives-japan-s-first-patent-for-ai-enabled-pharmacovigilance-system-validation 2025-12-04T09:25:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiropharmaconsulting-receives-japan-s-first-patent-for-ai-enabled-pharmacovigilance-system-validation 2025-12-04T09:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/argenica-s-arg-007-shows-promise-for-severe-stroke-patients-while-demonstrating-safety-compatibility-with-standard-clot-dissolving-therapies 2025-12-04T09:25:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenica-s-arg-007-shows-promise-for-severe-stroke-patients-while-demonstrating-safety-compatibility-with-standard-clot-dissolving-therapies 2025-12-04T09:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-establishes-india-as-largest-r-d-hub-outside-switzerland-with-9000-strong-workforce 2025-12-04T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-establishes-india-as-largest-r-d-hub-outside-switzerland-with-9000-strong-workforce 2025-12-04T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-proposes-major-overhaul-of-biosimilar-approval-process-eliminating-most-clinical-studies 2025-12-04T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-proposes-major-overhaul-of-biosimilar-approval-process-eliminating-most-clinical-studies 2025-12-04T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-12-04T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-companies-advancing-novel-therapies-through-clinical-trials 2025-12-04T07:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-announces-ceo-transition-as-pemvidutide-approaches-phase-3-readiness 2025-12-04T06:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-announces-ceo-transition-as-pemvidutide-approaches-phase-3-readiness 2025-12-04T06:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-completes-curevac-acquisition-with-81-74-shareholder-acceptance-consolidating-mrna-technology-portfolio 2025-12-04T06:39:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-completes-curevac-acquisition-with-81-74-shareholder-acceptance-consolidating-mrna-technology-portfolio 2025-12-04T06:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/transthera-s-tinengotinib-receives-priority-review-status-in-china-for-advanced-cholangiocarcinoma-treatment 2025-12-04T06:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transthera-s-tinengotinib-receives-priority-review-status-in-china-for-advanced-cholangiocarcinoma-treatment 2025-12-04T06:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/novabridge-s-ragistomig-shows-promise-in-checkpoint-inhibitor-resistant-cancers-with-new-q6w-dosing-schedule 2025-12-04T06:38:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novabridge-s-ragistomig-shows-promise-in-checkpoint-inhibitor-resistant-cancers-with-new-q6w-dosing-schedule 2025-12-04T06:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/vera-therapeutics-reports-positive-phase-3-igan-data-prompting-valuation-reassessment 2025-12-04T06:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vera-therapeutics-reports-positive-phase-3-igan-data-prompting-valuation-reassessment 2025-12-04T06:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-appoints-dr-hongjiang-miao-as-chief-ai-officer-to-advance-ai-driven-drug-discovery-strategy 2025-12-04T06:38:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-appoints-dr-hongjiang-miao-as-chief-ai-officer-to-advance-ai-driven-drug-discovery-strategy 2025-12-04T06:38:30+00:00 hourly 0.9 https://trial.medpath.com/news/impact-biotech-reports-70-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-upper-tract-urothelial-cancer 2025-12-04T06:38:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-biotech-reports-70-complete-response-rate-in-phase-3-enlighted-trial-of-padeliporfin-vtp-for-low-grade-upper-tract-urothelial-cancer 2025-12-04T06:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-ct-p70-adc-receives-fda-fast-track-designation-for-metastatic-lung-cancer 2025-12-04T06:38:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-s-ct-p70-adc-receives-fda-fast-track-designation-for-metastatic-lung-cancer 2025-12-04T06:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-receives-fda-biologics-license-approval-for-avance-nerve-allograft-marking-regulatory-milestone 2025-12-04T06:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axogen-receives-fda-biologics-license-approval-for-avance-nerve-allograft-marking-regulatory-milestone 2025-12-04T06:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-study-shows-promise-for-hiv-functional-cure-through-triple-immunotherapy-approach 2025-12-04T06:37:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-study-shows-promise-for-hiv-functional-cure-through-triple-immunotherapy-approach 2025-12-04T06:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/janx007-demonstrates-promising-efficacy-and-manageable-safety-profile-in-phase-1-metastatic-prostate-cancer-trial 2025-12-04T06:36:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janx007-demonstrates-promising-efficacy-and-manageable-safety-profile-in-phase-1-metastatic-prostate-cancer-trial 2025-12-04T06:36:58+00:00 hourly 0.9 https://trial.medpath.com/news/exmoor-pharma-and-ucl-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T06:36:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exmoor-pharma-and-ucl-form-strategic-partnership-to-accelerate-cell-and-gene-therapy-development 2025-12-04T06:36:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-mannkind-s-readyflow-autoinjector-application-for-rapid-furosemide-delivery-in-heart-failure 2025-12-04T06:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-mannkind-s-readyflow-autoinjector-application-for-rapid-furosemide-delivery-in-heart-failure 2025-12-04T06:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/larkspur-biosciences-initiates-first-in-human-trial-of-novel-protein-degrader-lrk-4189-for-colorectal-cancer 2025-12-04T06:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/larkspur-biosciences-initiates-first-in-human-trial-of-novel-protein-degrader-lrk-4189-for-colorectal-cancer 2025-12-04T06:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-biologics-secures-french-regulatory-approvals-for-gs010-lumevoq-gene-therapy-in-rare-blindness-disease 2025-12-04T06:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-biologics-secures-french-regulatory-approvals-for-gs010-lumevoq-gene-therapy-in-rare-blindness-disease 2025-12-04T06:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/lyric-bio-raises-6-6m-to-revolutionize-ivig-production-with-ultra-high-density-bioreactors 2025-12-04T06:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lyric-bio-raises-6-6m-to-revolutionize-ivig-production-with-ultra-high-density-bioreactors 2025-12-04T06:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-launches-phase-iii-trial-testing-mirena-iud-for-precancerous-uterine-condition-with-no-approved-treatments 2025-12-04T06:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-launches-phase-iii-trial-testing-mirena-iud-for-precancerous-uterine-condition-with-no-approved-treatments 2025-12-04T06:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/alpha-tau-receives-fda-approval-for-prostate-cancer-trial-and-presents-pancreatic-cancer-data-at-asco 2025-12-04T06:31:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alpha-tau-receives-fda-approval-for-prostate-cancer-trial-and-presents-pancreatic-cancer-data-at-asco 2025-12-04T06:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/tscan-therapeutics-announces-two-year-relapse-data-for-tsc-101-cell-therapy-ahead-of-pivotal-trial-launch 2025-12-04T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tscan-therapeutics-announces-two-year-relapse-data-for-tsc-101-cell-therapy-ahead-of-pivotal-trial-launch 2025-12-04T06:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/dogwood-therapeutics-secures-26-8m-financing-and-files-new-ip-protection-for-synthetic-halneuron-through-2045 2025-12-04T06:30:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dogwood-therapeutics-secures-26-8m-financing-and-files-new-ip-protection-for-synthetic-halneuron-through-2045 2025-12-04T06:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-solid-dispersion-techniques-show-promise-for-improving-tegoprazan-bioavailability-in-gerd-treatment 2025-12-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-solid-dispersion-techniques-show-promise-for-improving-tegoprazan-bioavailability-in-gerd-treatment 2025-12-04T06:30:18+00:00 hourly 0.9 https://trial.medpath.com/news/quralis-demonstrates-target-engagement-of-qrl-101-in-als-patients-advancing-precision-medicine-for-neurological-disorders 2025-12-04T06:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quralis-demonstrates-target-engagement-of-qrl-101-in-als-patients-advancing-precision-medicine-for-neurological-disorders 2025-12-04T06:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/soligenix-advances-hybryte-through-final-phase-3-trial-for-rare-cutaneous-t-cell-lymphoma 2025-12-04T06:27:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soligenix-advances-hybryte-through-final-phase-3-trial-for-rare-cutaneous-t-cell-lymphoma 2025-12-04T06:27:28+00:00 hourly 0.9 https://trial.medpath.com/news/immutep-s-eftilagimod-alfa-shows-strong-response-rates-in-metastatic-breast-cancer-establishes-optimal-dose-for-future-trials 2025-12-04T06:27:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutep-s-eftilagimod-alfa-shows-strong-response-rates-in-metastatic-breast-cancer-establishes-optimal-dose-for-future-trials 2025-12-04T06:27:13+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-faces-manufacturing-setback-as-fda-issues-warning-letter-to-catalent-partner-ahead-of-apitegromab-launch 2025-12-04T06:26:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-faces-manufacturing-setback-as-fda-issues-warning-letter-to-catalent-partner-ahead-of-apitegromab-launch 2025-12-04T06:26:02+00:00 hourly 0.9 https://trial.medpath.com/news/ventyx-expands-phase-2-recurrent-pericarditis-trial-internationally-adds-industry-veterans-to-advisory-board 2025-12-04T06:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ventyx-expands-phase-2-recurrent-pericarditis-trial-internationally-adds-industry-veterans-to-advisory-board 2025-12-04T06:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-court-rules-formulation-patents-ineligible-for-patent-term-extensions-in-landmark-otsuka-decision 2025-12-04T06:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-court-rules-formulation-patents-ineligible-for-patent-term-extensions-in-landmark-otsuka-decision 2025-12-04T06:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/major-mid-atlantic-insurer-expands-coverage-for-nerivio-migraine-device-providing-access-to-3-4-million-members 2025-12-04T06:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-mid-atlantic-insurer-expands-coverage-for-nerivio-migraine-device-providing-access-to-3-4-million-members 2025-12-04T06:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-cagrisema-outperforms-ozempic-in-diabetes-trial-company-plans-pediatric-obesity-study 2025-12-04T06:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-cagrisema-outperforms-ozempic-in-diabetes-trial-company-plans-pediatric-obesity-study 2025-12-04T06:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-reports-first-in-human-safety-data-for-novel-kcc2-direct-activator-ov350 2025-12-04T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-reports-first-in-human-safety-data-for-novel-kcc2-direct-activator-ov350 2025-12-04T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-her2-targeted-adcs-show-promise-in-breast-cancer-trials 2025-12-04T06:20:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-her2-targeted-adcs-show-promise-in-breast-cancer-trials 2025-12-04T06:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-low-dose-mri-contrast-agent-gadoquatrane-shows-promise-in-pediatric-study 2025-12-04T06:20:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-low-dose-mri-contrast-agent-gadoquatrane-shows-promise-in-pediatric-study 2025-12-04T06:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/lithium-shows-promise-in-suppressing-hiv-reactivation-through-novel-mechanism 2025-12-04T06:19:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lithium-shows-promise-in-suppressing-hiv-reactivation-through-novel-mechanism 2025-12-04T06:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/junevity-raises-20m-to-advance-first-in-class-sirna-cell-reprogramming-therapy-for-metabolic-disorders 2025-12-04T06:16:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/junevity-raises-20m-to-advance-first-in-class-sirna-cell-reprogramming-therapy-for-metabolic-disorders 2025-12-04T06:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-vaccine-provides-year-long-protection-against-deadly-allergic-reactions-in-mice 2025-12-04T06:16:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-vaccine-provides-year-long-protection-against-deadly-allergic-reactions-in-mice 2025-12-04T06:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/aspire-biopharma-advances-sublingual-aspirin-for-heart-attack-treatment-with-fda-pre-ind-submission 2025-12-04T06:15:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspire-biopharma-advances-sublingual-aspirin-for-heart-attack-treatment-with-fda-pre-ind-submission 2025-12-04T06:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/ultragenyx-advances-multiple-gene-therapies-toward-regulatory-approval-with-dtx401-bla-submission 2025-12-04T06:15:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultragenyx-advances-multiple-gene-therapies-toward-regulatory-approval-with-dtx401-bla-submission 2025-12-04T06:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/robust-aml-clinical-pipeline-shows-promise-with-100-companies-developing-novel-therapies 2025-12-04T06:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-aml-clinical-pipeline-shows-promise-with-100-companies-developing-novel-therapies 2025-12-04T06:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/foresight-diagnostics-showcases-ultrasensitive-mrd-technology-in-multiple-lymphoma-studies-at-ash-2025 2025-12-04T06:14:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresight-diagnostics-showcases-ultrasensitive-mrd-technology-in-multiple-lymphoma-studies-at-ash-2025 2025-12-04T06:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-and-mayo-clinic-launch-gemini-rt-initiative-to-transform-personalized-radiation-therapy 2025-12-04T06:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-and-mayo-clinic-launch-gemini-rt-initiative-to-transform-personalized-radiation-therapy 2025-12-04T06:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-shows-adalimumab-biosimilars-maintain-efficacy-despite-injection-site-tolerability-concerns 2025-12-04T06:13:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-shows-adalimumab-biosimilars-maintain-efficacy-despite-injection-site-tolerability-concerns 2025-12-04T06:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/rentschler-biopharma-and-coriolis-pharma-form-strategic-alliance-to-deliver-integrated-biopharmaceutical-solutions 2025-12-04T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rentschler-biopharma-and-coriolis-pharma-form-strategic-alliance-to-deliver-integrated-biopharmaceutical-solutions 2025-12-04T06:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-francis-medical-s-vanquish-water-vapor-system-for-intermediate-risk-prostate-cancer-treatment 2025-12-04T06:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-francis-medical-s-vanquish-water-vapor-system-for-intermediate-risk-prostate-cancer-treatment 2025-12-04T06:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/epcoritamab-demonstrates-strong-efficacy-in-elderly-dlbcl-and-follicular-lymphoma-patients-at-ash-2024 2025-12-04T06:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epcoritamab-demonstrates-strong-efficacy-in-elderly-dlbcl-and-follicular-lymphoma-patients-at-ash-2024 2025-12-04T06:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-receives-fda-clearance-for-hugo-robotic-surgery-system-in-urology-procedures 2025-12-04T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-receives-fda-clearance-for-hugo-robotic-surgery-system-in-urology-procedures 2025-12-04T06:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-to-launch-ozempic-in-india-this-december-as-competition-intensifies-in-150-billion-weight-loss-market 2025-12-04T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-to-launch-ozempic-in-india-this-december-as-competition-intensifies-in-150-billion-weight-loss-market 2025-12-04T06:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/uk-clinical-trial-recruitment-drops-25-despite-government-reform-efforts 2025-12-04T06:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-clinical-trial-recruitment-drops-25-despite-government-reform-efforts 2025-12-04T06:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-commits-40-million-to-indiana-university-for-ai-enhanced-clinical-trial-infrastructure 2025-12-04T06:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-commits-40-million-to-indiana-university-for-ai-enhanced-clinical-trial-infrastructure 2025-12-04T06:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridemia 2025-12-04T06:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy-designation-for-plozasiran-in-severe-hypertriglyceridemia 2025-12-04T06:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reduces-surveillance-requirements-for-seastar-medical-s-pediatric-aki-therapy-following-promising-safety-data 2025-12-04T06:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reduces-surveillance-requirements-for-seastar-medical-s-pediatric-aki-therapy-following-promising-safety-data 2025-12-04T06:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-advances-12-billion-acquisition-of-avidity-biosciences-for-rna-therapeutics-platform 2025-12-04T06:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-advances-12-billion-acquisition-of-avidity-biosciences-for-rna-therapeutics-platform 2025-12-04T06:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-pharmaceuticals-completes-bla-submission-for-first-in-class-dna-immunotherapy-ino-3107 2025-12-04T06:03:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-pharmaceuticals-completes-bla-submission-for-first-in-class-dna-immunotherapy-ino-3107 2025-12-04T06:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/santen-and-singapore-eye-research-institute-launch-21-million-collaboration-to-develop-disease-modifying-eye-therapies 2025-12-04T06:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/santen-and-singapore-eye-research-institute-launch-21-million-collaboration-to-develop-disease-modifying-eye-therapies 2025-12-04T06:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/virax-biolabs-advances-post-acute-infection-syndrome-diagnostics-with-completed-uk-trial-recruitment-and-fda-engagement 2025-12-04T06:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virax-biolabs-advances-post-acute-infection-syndrome-diagnostics-with-completed-uk-trial-recruitment-and-fda-engagement 2025-12-04T06:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-cardiolrx-shows-significant-cardiac-benefits-in-phase-ii-myocarditis-trial 2025-12-04T06:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiol-therapeutics-cardiolrx-shows-significant-cardiac-benefits-in-phase-ii-myocarditis-trial 2025-12-04T06:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/ltr-pharma-receives-ethics-approval-for-spontan-phase-2-trial-targeting-elderly-erectile-dysfunction-patients 2025-12-04T06:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltr-pharma-receives-ethics-approval-for-spontan-phase-2-trial-targeting-elderly-erectile-dysfunction-patients 2025-12-04T06:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-advances-multi-asset-pipeline-with-phase-2-progress-and-orphan-drug-designation 2025-12-04T06:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-advances-multi-asset-pipeline-with-phase-2-progress-and-orphan-drug-designation 2025-12-04T06:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-demonstrates-68-fold-increase-in-brain-delivery-for-alzheimer-s-antibody-using-novel-transferrin-receptor-technology 2025-12-04T06:00:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-demonstrates-68-fold-increase-in-brain-delivery-for-alzheimer-s-antibody-using-novel-transferrin-receptor-technology 2025-12-04T06:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/renerva-receives-fda-approval-for-first-in-human-trial-of-novel-nerve-capping-device-to-prevent-chronic-amputation-pain 2025-12-04T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renerva-receives-fda-approval-for-first-in-human-trial-of-novel-nerve-capping-device-to-prevent-chronic-amputation-pain 2025-12-04T05:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-in-preclinical-study 2025-12-04T05:58:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aethlon-medical-s-hemopurifier-shows-promise-for-long-covid-treatment-in-preclinical-study 2025-12-04T05:58:50+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-advances-regulatory-pathways-for-cordstrom-and-xpro1595-programs 2025-12-04T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-advances-regulatory-pathways-for-cordstrom-and-xpro1595-programs 2025-12-04T05:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/granata-bio-advances-phase-iii-grace-study-for-investigational-gonadotropin-in-ivf-treatment 2025-12-04T05:57:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/granata-bio-advances-phase-iii-grace-study-for-investigational-gonadotropin-in-ivf-treatment 2025-12-04T05:57:57+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-key-u-s-patent-for-udenafil-in-fontan-patients-extending-exclusivity-to-early-2040s 2025-12-04T05:57:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mezzion-secures-key-u-s-patent-for-udenafil-in-fontan-patients-extending-exclusivity-to-early-2040s 2025-12-04T05:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/amplia-therapeutics-secures-u-s-patent-protection-for-fak-inhibitor-narmafotinib-through-2040 2025-12-04T05:56:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amplia-therapeutics-secures-u-s-patent-protection-for-fak-inhibitor-narmafotinib-through-2040 2025-12-04T05:56:53+00:00 hourly 0.9 https://trial.medpath.com/news/rondo-therapeutics-initiates-first-in-human-trial-of-rndo-564-novel-bispecific-antibody-for-advanced-solid-tumors 2025-12-04T05:55:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rondo-therapeutics-initiates-first-in-human-trial-of-rndo-564-novel-bispecific-antibody-for-advanced-solid-tumors 2025-12-04T05:55:39+00:00 hourly 0.9 https://trial.medpath.com/news/archeus-technologies-initiates-first-in-human-trial-of-art-101-psma-targeting-radioligand-therapy-for-metastatic-prostate-cancer 2025-12-04T05:55:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archeus-technologies-initiates-first-in-human-trial-of-art-101-psma-targeting-radioligand-therapy-for-metastatic-prostate-cancer 2025-12-04T05:55:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-expanded-approval-for-eli-lilly-s-jaypirca-in-earlier-line-cll-sll-treatment 2025-12-04T05:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-expanded-approval-for-eli-lilly-s-jaypirca-in-earlier-line-cll-sll-treatment 2025-12-04T05:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/sutro-biopharma-initiates-phase-1-trial-of-stro-004-next-generation-tissue-factor-adc-for-advanced-solid-tumors 2025-12-04T05:55:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sutro-biopharma-initiates-phase-1-trial-of-stro-004-next-generation-tissue-factor-adc-for-advanced-solid-tumors 2025-12-04T05:55:27+00:00 hourly 0.9 https://trial.medpath.com/news/armr-sciences-initiates-first-human-trials-for-fentanyl-vaccine-in-early-2025 2025-12-04T05:54:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/armr-sciences-initiates-first-human-trials-for-fentanyl-vaccine-in-early-2025 2025-12-04T05:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-receives-fda-support-for-d-plex100-nda-submission-following-positive-pre-nda-meeting 2025-12-04T05:54:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polypid-receives-fda-support-for-d-plex100-nda-submission-following-positive-pre-nda-meeting 2025-12-04T05:54:25+00:00 hourly 0.9 https://trial.medpath.com/news/muvon-therapeutics-reports-breakthrough-phase-2-results-for-muscle-cell-based-stress-urinary-incontinence-therapy 2025-12-04T05:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/muvon-therapeutics-reports-breakthrough-phase-2-results-for-muscle-cell-based-stress-urinary-incontinence-therapy 2025-12-04T05:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/hemophilia-gene-therapies-face-market-struggles-despite-scientific-promise 2025-12-04T05:53:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hemophilia-gene-therapies-face-market-struggles-despite-scientific-promise 2025-12-04T05:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-cryoneurolysis-device-shows-superior-pain-relief-over-radiofrequency-ablation-in-chronic-low-back-pain-study 2025-12-04T05:53:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-s-cryoneurolysis-device-shows-superior-pain-relief-over-radiofrequency-ablation-in-chronic-low-back-pain-study 2025-12-04T05:53:23+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-conditional-marketing-authorization-for-immunitybio-s-anktiva-in-bladder-cancer 2025-12-04T05:53:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-conditional-marketing-authorization-for-immunitybio-s-anktiva-in-bladder-cancer 2025-12-04T05:53:18+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-shows-superior-performance-in-lymphoma-detection-at-ash-2025 2025-12-04T05:52:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-shows-superior-performance-in-lymphoma-detection-at-ash-2025 2025-12-04T05:52:34+00:00 hourly 0.9 https://trial.medpath.com/news/strm-bio-secures-8-4m-arpa-h-contract-to-develop-novel-extracellular-vesicle-platform-for-in-vivo-car-t-cell-engineering 2025-12-04T05:49:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strm-bio-secures-8-4m-arpa-h-contract-to-develop-novel-extracellular-vesicle-platform-for-in-vivo-car-t-cell-engineering 2025-12-04T05:49:54+00:00 hourly 0.9 https://trial.medpath.com/news/onco3r-therapeutics-reports-positive-phase-1-data-for-novel-sik3-inhibitor-o3r-5671-in-autoimmune-disease-treatment 2025-12-04T05:49:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco3r-therapeutics-reports-positive-phase-1-data-for-novel-sik3-inhibitor-o3r-5671-in-autoimmune-disease-treatment 2025-12-04T05:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-nt-100-million-gene-therapy-for-rare-aadc-deficiency-amid-coverage-debate 2025-12-04T05:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-approves-nt-100-million-gene-therapy-for-rare-aadc-deficiency-amid-coverage-debate 2025-12-04T05:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-s-tinlarebant-achieves-35-7-reduction-in-lesion-growth-in-first-successful-phase-3-trial-for-stargardt-disease 2025-12-04T05:44:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-s-tinlarebant-achieves-35-7-reduction-in-lesion-growth-in-first-successful-phase-3-trial-for-stargardt-disease 2025-12-04T05:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-virginia-launches-clinical-trial-for-new-covid-19-treatment-targeting-outpatients 2025-12-04T05:44:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-virginia-launches-clinical-trial-for-new-covid-19-treatment-targeting-outpatients 2025-12-04T05:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/australia-issues-new-safety-warnings-for-glp-1-drugs-following-reports-of-suicidal-thoughts 2025-12-04T05:44:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-issues-new-safety-warnings-for-glp-1-drugs-following-reports-of-suicidal-thoughts 2025-12-04T05:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-lomb-partners-with-ripple-therapeutics-to-develop-polymer-free-sustained-release-ophthalmic-implants 2025-12-04T05:43:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-lomb-partners-with-ripple-therapeutics-to-develop-polymer-free-sustained-release-ophthalmic-implants 2025-12-04T05:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-reports-positive-phase-1b-data-for-briquilimab-in-asthma-completes-beacon-study-investigation 2025-12-04T05:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-reports-positive-phase-1b-data-for-briquilimab-in-asthma-completes-beacon-study-investigation 2025-12-04T05:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-fda-clearance-for-15-minute-point-of-care-bordetella-pcr-test 2025-12-04T05:42:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-receives-fda-clearance-for-15-minute-point-of-care-bordetella-pcr-test 2025-12-04T05:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/two-companies-launch-competing-glp-1-clinical-trials-for-feline-weight-management 2025-12-04T05:41:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-companies-launch-competing-glp-1-clinical-trials-for-feline-weight-management 2025-12-04T05:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/akiram-therapeutics-advances-cd44v6-targeted-radiotherapy-akir001-with-cohort-2b-clearance-and-journal-publication 2025-12-04T05:40:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akiram-therapeutics-advances-cd44v6-targeted-radiotherapy-akir001-with-cohort-2b-clearance-and-journal-publication 2025-12-04T05:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-alert-after-seven-deaths-linked-to-abbott-freestyle-libre-3-glucose-monitor-defects 2025-12-04T05:39:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-alert-after-seven-deaths-linked-to-abbott-freestyle-libre-3-glucose-monitor-defects 2025-12-04T05:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-pricing-agreements-open-market-for-new-obesity-drug-competitors 2025-12-04T05:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-pricing-agreements-open-market-for-new-obesity-drug-competitors 2025-12-04T05:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/lotus-pharma-submits-first-regulatory-application-for-vizz-presbyopia-treatment-in-south-korea 2025-12-04T05:37:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lotus-pharma-submits-first-regulatory-application-for-vizz-presbyopia-treatment-in-south-korea 2025-12-04T05:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/4d-path-s-ai-platform-predicts-chemotherapy-response-in-triple-negative-breast-cancer-using-standard-biopsy-images 2025-12-04T05:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4d-path-s-ai-platform-predicts-chemotherapy-response-in-triple-negative-breast-cancer-using-standard-biopsy-images 2025-12-04T05:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/outlook-therapeutics-awaits-critical-fda-decision-on-first-ophthalmic-bevacizumab-for-wet-amd-by-december-31 2025-12-04T05:37:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outlook-therapeutics-awaits-critical-fda-decision-on-first-ophthalmic-bevacizumab-for-wet-amd-by-december-31 2025-12-04T05:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/automated-lung-organoid-production-breakthrough-promises-to-accelerate-respiratory-drug-development 2025-12-04T05:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-lung-organoid-production-breakthrough-promises-to-accelerate-respiratory-drug-development 2025-12-04T05:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-receives-fda-guidance-for-phase-3-panda-study-of-68ga-pentixafor-in-primary-aldosteronism 2025-12-04T05:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pentixapharm-receives-fda-guidance-for-phase-3-panda-study-of-68ga-pentixafor-in-primary-aldosteronism 2025-12-04T05:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/excelsior-sciences-secures-95-million-to-revolutionize-ai-driven-small-molecule-drug-discovery 2025-12-04T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excelsior-sciences-secures-95-million-to-revolutionize-ai-driven-small-molecule-drug-discovery 2025-12-04T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/quadriga-biosciences-reports-promising-phase-iia-results-for-qbs72s-in-breast-cancer-leptomeningeal-disease 2025-12-04T05:37:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quadriga-biosciences-reports-promising-phase-iia-results-for-qbs72s-in-breast-cancer-leptomeningeal-disease 2025-12-04T05:37:01+00:00 hourly 0.9 https://trial.medpath.com/news/protara-s-tara-002-shows-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T05:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protara-s-tara-002-shows-72-complete-response-rate-in-bcg-naive-bladder-cancer-patients 2025-12-04T05:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/relmada-therapeutics-presents-promising-6-month-data-for-ndv-01-bladder-cancer-treatment-at-urologic-oncology-meeting 2025-12-04T05:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relmada-therapeutics-presents-promising-6-month-data-for-ndv-01-bladder-cancer-treatment-at-urologic-oncology-meeting 2025-12-04T05:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/illumina-and-myome-partner-to-advance-200-billion-healthcare-savings-through-ai-driven-genomic-medicine 2025-12-04T05:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illumina-and-myome-partner-to-advance-200-billion-healthcare-savings-through-ai-driven-genomic-medicine 2025-12-04T05:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-olastrocel-as-international-name-for-creative-medical-s-lead-cell-therapy-celz-201 2025-12-04T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-olastrocel-as-international-name-for-creative-medical-s-lead-cell-therapy-celz-201 2025-12-04T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-accelerated-approval-to-otsuka-s-voyxact-for-iga-nephropathy-first-april-targeting-therapy 2025-12-04T05:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-to-otsuka-s-voyxact-for-iga-nephropathy-first-april-targeting-therapy 2025-12-04T05:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/cms-approves-47-payment-increase-for-optical-genome-mapping-in-blood-cancer-diagnostics 2025-12-04T05:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-approves-47-payment-increase-for-optical-genome-mapping-in-blood-cancer-diagnostics 2025-12-04T05:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/two-novel-alzheimer-s-therapies-advance-in-phase-2-trials-oral-pri-002-and-trem2-targeting-vhb937 2025-12-04T05:33:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-novel-alzheimer-s-therapies-advance-in-phase-2-trials-oral-pri-002-and-trem2-targeting-vhb937 2025-12-04T05:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/federal-appeals-court-overturns-41-million-patent-verdict-against-daiichi-sankyo-s-enhertu-adc 2025-12-04T05:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-appeals-court-overturns-41-million-patent-verdict-against-daiichi-sankyo-s-enhertu-adc 2025-12-04T05:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-300mg-strength-of-celltrion-s-omlyclo-first-interchangeable-biosimilar-to-xolair 2025-12-04T05:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-300mg-strength-of-celltrion-s-omlyclo-first-interchangeable-biosimilar-to-xolair 2025-12-04T05:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/jaguar-health-seeks-ema-approval-for-canalevia-in-european-union-to-treat-general-diarrhea-in-dogs 2025-12-04T05:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jaguar-health-seeks-ema-approval-for-canalevia-in-european-union-to-treat-general-diarrhea-in-dogs 2025-12-04T05:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-bioepis-secures-european-approval-for-byooviz-pre-filled-syringe-formulation 2025-12-04T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-bioepis-secures-european-approval-for-byooviz-pre-filled-syringe-formulation 2025-12-04T05:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-extended-patent-protection-for-mpar-overdose-prevention-technology-through-2042 2025-12-04T05:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-secures-extended-patent-protection-for-mpar-overdose-prevention-technology-through-2042 2025-12-04T05:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-appoints-former-nimbus-ceo-jeb-keiper-to-board-as-company-advances-programmable-mrna-platform 2025-12-04T05:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-appoints-former-nimbus-ceo-jeb-keiper-to-board-as-company-advances-programmable-mrna-platform 2025-12-04T05:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-pharmaceutical-patent-linkage-system-shows-growing-judicial-maturity-after-four-years-of-operation 2025-12-04T05:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-pharmaceutical-patent-linkage-system-shows-growing-judicial-maturity-after-four-years-of-operation 2025-12-04T05:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-first-in-class-vectorized-antibody-trial-for-als-targeting-tdp-43-pathology 2025-12-04T05:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-first-in-class-vectorized-antibody-trial-for-als-targeting-tdp-43-pathology 2025-12-04T05:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/jupiter-neurosciences-advances-jotrol-into-phase-2a-parkinson-s-trial-following-fda-clearance 2025-12-04T05:31:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jupiter-neurosciences-advances-jotrol-into-phase-2a-parkinson-s-trial-following-fda-clearance 2025-12-04T05:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/leqembi-shows-measurable-target-engagement-with-alzheimer-s-protofibrils-in-cerebrospinal-fluid 2025-12-04T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leqembi-shows-measurable-target-engagement-with-alzheimer-s-protofibrils-in-cerebrospinal-fluid 2025-12-04T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-faces-regulatory-headwinds-as-fda-signals-stricter-vaccine-approval-standards 2025-12-04T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-faces-regulatory-headwinds-as-fda-signals-stricter-vaccine-approval-standards 2025-12-04T05:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/nrx-pharmaceuticals-expands-nrx-101-development-to-include-combination-therapy-with-transcranial-magnetic-stimulation-for-depression 2025-12-04T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrx-pharmaceuticals-expands-nrx-101-development-to-include-combination-therapy-with-transcranial-magnetic-stimulation-for-depression 2025-12-04T05:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-s-clascoterone-5-topical-solution-achieves-breakthrough-results-in-phase-iii-male-pattern-hair-loss-trials 2025-12-04T05:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-s-clascoterone-5-topical-solution-achieves-breakthrough-results-in-phase-iii-male-pattern-hair-loss-trials 2025-12-04T05:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/avecho-biotechnology-secures-us-and-eu-patent-protection-for-cbd-insomnia-treatment-through-2040 2025-12-04T05:31:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avecho-biotechnology-secures-us-and-eu-patent-protection-for-cbd-insomnia-treatment-through-2040 2025-12-04T05:31:22+00:00 hourly 0.9 https://trial.medpath.com/news/aob-pharma-secures-ema-pediatric-investigation-plan-approval-for-b244-atopic-dermatitis-treatment-with-topical-corticosteroid-waiver 2025-12-04T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aob-pharma-secures-ema-pediatric-investigation-plan-approval-for-b244-atopic-dermatitis-treatment-with-topical-corticosteroid-waiver 2025-12-04T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/triana-biomedicines-secures-120m-series-b-to-advance-alk-targeted-molecular-glue-degrader-for-lung-cancer 2025-12-04T05:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triana-biomedicines-secures-120m-series-b-to-advance-alk-targeted-molecular-glue-degrader-for-lung-cancer 2025-12-04T05:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/paradigm-trial-shows-venetoclax-azacitidine-superior-to-intensive-chemotherapy-in-newly-diagnosed-aml 2025-12-04T05:29:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paradigm-trial-shows-venetoclax-azacitidine-superior-to-intensive-chemotherapy-in-newly-diagnosed-aml 2025-12-04T05:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/citizen-health-and-ucb-launch-strategic-partnership-to-accelerate-epilepsy-and-rare-disease-drug-development-using-ai 2025-12-04T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citizen-health-and-ucb-launch-strategic-partnership-to-accelerate-epilepsy-and-rare-disease-drug-development-using-ai 2025-12-04T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-12-04T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-enfortumab-vedotin-plus-pembrolizumab-for-perioperative-treatment-of-muscle-invasive-bladder-cancer 2025-12-04T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/greenwich-lifesciences-completes-enrollment-in-non-hla-a-02-arm-of-phase-iii-flamingo-01-trial-for-breast-cancer-prevention 2025-12-04T05:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenwich-lifesciences-completes-enrollment-in-non-hla-a-02-arm-of-phase-iii-flamingo-01-trial-for-breast-cancer-prevention 2025-12-04T05:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/abemaciclib-monotherapy-shows-promise-after-cdk4-6-inhibitor-failure-in-hr-her2-breast-cancer 2025-12-04T05:28:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abemaciclib-monotherapy-shows-promise-after-cdk4-6-inhibitor-failure-in-hr-her2-breast-cancer 2025-12-04T05:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/alkeus-pharmaceuticals-appoints-carlos-quezada-ruiz-as-chief-medical-officer-to-lead-stargardt-disease-drug-development 2025-12-04T05:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-appoints-carlos-quezada-ruiz-as-chief-medical-officer-to-lead-stargardt-disease-drug-development 2025-12-04T05:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-amneal-s-generic-cyclosporine-eye-drops-for-dry-eye-disease-treatment 2025-12-04T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-amneal-s-generic-cyclosporine-eye-drops-for-dry-eye-disease-treatment 2025-12-04T05:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-submits-fda-application-for-ameluz-pdt-in-superficial-basal-cell-carcinoma-treatment 2025-12-04T05:28:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-submits-fda-application-for-ameluz-pdt-in-superficial-basal-cell-carcinoma-treatment 2025-12-04T05:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma-following-landmark-aquila-trial-results 2025-12-04T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-daratumumab-for-high-risk-smoldering-multiple-myeloma-following-landmark-aquila-trial-results 2025-12-04T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/zynlonta-plus-glofitamab-achieves-89-8-response-rate-in-relapsed-refractory-dlbcl-trial 2025-12-04T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zynlonta-plus-glofitamab-achieves-89-8-response-rate-in-relapsed-refractory-dlbcl-trial 2025-12-04T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/alzecure-receives-eur2-5-million-eu-grant-to-advance-phase-2a-trial-of-novel-alzheimer-s-drug-acd856 2025-12-04T05:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzecure-receives-eur2-5-million-eu-grant-to-advance-phase-2a-trial-of-novel-alzheimer-s-drug-acd856 2025-12-04T05:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-to-present-phase-3-epx-100-data-for-dravet-syndrome-at-aes-annual-meeting 2025-12-04T05:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-to-present-phase-3-epx-100-data-for-dravet-syndrome-at-aes-annual-meeting 2025-12-04T05:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/elevar-s-rivoceranib-camrelizumab-combination-shows-significant-survival-benefit-in-phase-3-liver-cancer-trial 2025-12-04T05:27:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevar-s-rivoceranib-camrelizumab-combination-shows-significant-survival-benefit-in-phase-3-liver-cancer-trial 2025-12-04T05:27:30+00:00 hourly 0.9 https://trial.medpath.com/news/savara-secures-european-patent-protection-for-molbreevi-through-2041-strengthening-ip-portfolio-for-rare-lung-disease-therapy 2025-12-04T05:27:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/savara-secures-european-patent-protection-for-molbreevi-through-2041-strengthening-ip-portfolio-for-rare-lung-disease-therapy 2025-12-04T05:27:24+00:00 hourly 0.9 https://trial.medpath.com/news/sagent-pharmaceuticals-partners-with-provepharm-to-launch-bludigo-first-fda-approved-injectable-indigo-carmine-diagnostic-dye 2025-12-04T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagent-pharmaceuticals-partners-with-provepharm-to-launch-bludigo-first-fda-approved-injectable-indigo-carmine-diagnostic-dye 2025-12-04T05:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-receives-135-million-milestone-payment-as-komzifti-achieves-first-commercial-sale 2025-12-04T05:26:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-receives-135-million-milestone-payment-as-komzifti-achieves-first-commercial-sale 2025-12-04T05:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/pharvaris-reports-positive-phase-3-results-for-oral-hae-treatment-deucrictibant 2025-12-04T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharvaris-reports-positive-phase-3-results-for-oral-hae-treatment-deucrictibant 2025-12-04T05:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/latus-bio-receives-fda-ind-clearance-for-lts-101-gene-therapy-to-treat-fatal-cln2-disease-in-children 2025-12-04T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latus-bio-receives-fda-ind-clearance-for-lts-101-gene-therapy-to-treat-fatal-cln2-disease-in-children 2025-12-04T05:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/immuron-secures-us-department-of-defense-award-for-novel-oral-therapeutics-against-military-priority-pathogens 2025-12-04T05:26:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuron-secures-us-department-of-defense-award-for-novel-oral-therapeutics-against-military-priority-pathogens 2025-12-04T05:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/pedmark-shows-significant-reduction-in-cisplatin-induced-hearing-loss-in-japanese-pediatric-cancer-study 2025-12-04T05:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pedmark-shows-significant-reduction-in-cisplatin-induced-hearing-loss-in-japanese-pediatric-cancer-study 2025-12-04T05:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/incannex-healthcare-receives-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T05:24:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incannex-healthcare-receives-fda-fast-track-designation-for-ihl-42x-in-obstructive-sleep-apnea 2025-12-04T05:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/iolyx-therapeutics-secures-280m-partnership-with-laboratoires-thea-for-autoimmune-dry-eye-treatment 2025-12-04T05:24:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iolyx-therapeutics-secures-280m-partnership-with-laboratoires-thea-for-autoimmune-dry-eye-treatment 2025-12-04T05:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-secures-fda-approval-for-generic-albuterol-inhaler-marking-second-respiratory-win-in-q4-2025 2025-12-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-secures-fda-approval-for-generic-albuterol-inhaler-marking-second-respiratory-win-in-q4-2025 2025-12-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/silexion-therapeutics-receives-german-regulatory-approval-for-phase-2-3-pancreatic-cancer-trial-design 2025-12-04T05:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silexion-therapeutics-receives-german-regulatory-approval-for-phase-2-3-pancreatic-cancer-trial-design 2025-12-04T05:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-presents-breakthrough-data-at-ash-2025-demonstrating-significant-advances-in-blood-cancer-treatment 2025-12-04T05:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-presents-breakthrough-data-at-ash-2025-demonstrating-significant-advances-in-blood-cancer-treatment 2025-12-04T05:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/black-diamond-therapeutics-to-present-phase-2-silevertinib-results-for-egfr-mutant-nsclc 2025-12-04T05:23:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-diamond-therapeutics-to-present-phase-2-silevertinib-results-for-egfr-mutant-nsclc 2025-12-04T05:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-allows-dr-reddy-s-to-export-semaglutide-challenges-novo-nordisk-patent-validity 2025-12-04T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-allows-dr-reddy-s-to-export-semaglutide-challenges-novo-nordisk-patent-validity 2025-12-04T05:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/tiakis-biotech-advances-tiprelestat-to-phase-ii-trial-for-pulmonary-arterial-hypertension-following-positive-safety-data 2025-12-04T05:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tiakis-biotech-advances-tiprelestat-to-phase-ii-trial-for-pulmonary-arterial-hypertension-following-positive-safety-data 2025-12-04T05:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/quetzal-therapeutics-initiates-phase-iii-trial-of-oral-arsenic-trioxide-qtx-2101-for-acute-promyelocytic-leukemia 2025-12-04T05:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quetzal-therapeutics-initiates-phase-iii-trial-of-oral-arsenic-trioxide-qtx-2101-for-acute-promyelocytic-leukemia 2025-12-04T05:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-approves-tisotumab-vedotin-for-recurrent-cervical-cancer-demonstrating-30-reduction-in-death-risk 2025-12-04T05:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-approves-tisotumab-vedotin-for-recurrent-cervical-cancer-demonstrating-30-reduction-in-death-risk 2025-12-04T05:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-wave-of-oncology-drugs-and-biosimilars-in-november-2025-expanding-treatment-access 2025-12-04T05:22:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-wave-of-oncology-drugs-and-biosimilars-in-november-2025-expanding-treatment-access 2025-12-04T05:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ziftomenib-first-in-class-targeted-therapy-for-npm1-mutated-acute-myeloid-leukemia 2025-12-04T05:22:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ziftomenib-first-in-class-targeted-therapy-for-npm1-mutated-acute-myeloid-leukemia 2025-12-04T05:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-delays-cobenfy-alzheimer-s-psychosis-trial-results-to-2026-following-site-irregularities 2025-12-04T05:21:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-delays-cobenfy-alzheimer-s-psychosis-trial-results-to-2026-following-site-irregularities 2025-12-04T05:21:28+00:00 hourly 0.9 https://trial.medpath.com/news/vandria-s-vna-318-shows-promising-phase-1-results-with-novel-dual-action-mechanism-for-alzheimer-s-disease 2025-12-04T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vandria-s-vna-318-shows-promising-phase-1-results-with-novel-dual-action-mechanism-for-alzheimer-s-disease 2025-12-04T05:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/polaritybio-completes-phase-iii-trial-of-skinte-for-diabetic-foot-ulcers-targets-first-bla-approval-since-1997 2025-12-04T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polaritybio-completes-phase-iii-trial-of-skinte-for-diabetic-foot-ulcers-targets-first-bla-approval-since-1997 2025-12-04T05:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-remote-monitoring-shows-promise-for-reducing-patient-burden-in-clinical-trials 2025-12-04T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-remote-monitoring-shows-promise-for-reducing-patient-burden-in-clinical-trials 2025-12-04T05:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-shows-92-amyloid-clearance-success-in-alzheimer-s-mid-stage-trial 2025-12-04T05:21:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-trontinemab-shows-92-amyloid-clearance-success-in-alzheimer-s-mid-stage-trial 2025-12-04T05:21:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-chief-claims-covid-19-vaccines-linked-to-10-pediatric-deaths-sparking-expert-criticism-and-market-decline 2025-12-04T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-chief-claims-covid-19-vaccines-linked-to-10-pediatric-deaths-sparking-expert-criticism-and-market-decline 2025-12-04T05:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-house-passes-bipartisan-bill-to-reauthorize-fda-s-rare-pediatric-disease-priority-review-voucher-program 2025-12-04T05:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-house-passes-bipartisan-bill-to-reauthorize-fda-s-rare-pediatric-disease-priority-review-voucher-program 2025-12-04T05:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-trontinemab-shows-92-success-rate-in-clearing-alzheimer-s-amyloid-plaques 2025-12-04T05:20:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-trontinemab-shows-92-success-rate-in-clearing-alzheimer-s-amyloid-plaques 2025-12-04T05:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-deploys-agentic-ai-across-agency-to-accelerate-drug-reviews-and-modernize-regulatory-workflows 2025-12-04T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-deploys-agentic-ai-across-agency-to-accelerate-drug-reviews-and-modernize-regulatory-workflows 2025-12-04T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-proposes-7-25-billion-roundup-settlement-as-trump-administration-backs-supreme-court-appeal 2025-12-03T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-proposes-7-25-billion-roundup-settlement-as-trump-administration-backs-supreme-court-appeal 2025-12-03T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-appoints-carolyn-bonner-as-cfo-while-advancing-multiple-clinical-programs 2025-12-03T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-appoints-carolyn-bonner-as-cfo-while-advancing-multiple-clinical-programs 2025-12-03T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-evaluates-pevonedistat-capecitabine-oxaliplatin-combination-for-advanced-gastric-cancer 2025-12-03T08:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-trial-evaluates-pevonedistat-capecitabine-oxaliplatin-combination-for-advanced-gastric-cancer 2025-12-03T08:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/imvax-plans-fda-discussions-for-glioblastoma-therapy-despite-missing-primary-endpoint 2025-12-03T06:27:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imvax-plans-fda-discussions-for-glioblastoma-therapy-despite-missing-primary-endpoint 2025-12-03T06:27:05+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-study-identifies-z-endoxifen-as-promising-therapeutic-candidate-for-glioblastoma 2025-12-03T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-study-identifies-z-endoxifen-as-promising-therapeutic-candidate-for-glioblastoma 2025-12-03T06:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/curi-bio-raises-10m-series-b-to-scale-human-ipsc-platforms-for-drug-discovery 2025-12-03T06:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curi-bio-raises-10m-series-b-to-scale-human-ipsc-platforms-for-drug-discovery 2025-12-03T06:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/diagnostear-partners-with-alyatec-for-clinical-validation-of-revolutionary-red-eye-diagnostic-test 2025-12-03T06:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diagnostear-partners-with-alyatec-for-clinical-validation-of-revolutionary-red-eye-diagnostic-test 2025-12-03T06:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-secures-fda-approval-for-imdelltra-in-small-cell-lung-cancer-as-pipeline-advances-drive-growth 2025-12-03T06:25:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-secures-fda-approval-for-imdelltra-in-small-cell-lung-cancer-as-pipeline-advances-drive-growth 2025-12-03T06:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-birchbiomed-s-fs2-for-idiopathic-pulmonary-fibrosis-treatment 2025-12-03T06:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-birchbiomed-s-fs2-for-idiopathic-pulmonary-fibrosis-treatment 2025-12-03T06:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/engene-s-detalimogene-selected-for-fda-manufacturing-pilot-program-to-accelerate-bladder-cancer-gene-therapy-development 2025-12-03T06:25:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engene-s-detalimogene-selected-for-fda-manufacturing-pilot-program-to-accelerate-bladder-cancer-gene-therapy-development 2025-12-03T06:25:06+00:00 hourly 0.9 https://trial.medpath.com/news/uk-secures-zero-tariff-us-pharmaceutical-deal-with-25-increase-in-nhs-medicine-investment 2025-12-03T06:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-secures-zero-tariff-us-pharmaceutical-deal-with-25-increase-in-nhs-medicine-investment 2025-12-03T06:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/electra-therapeutics-advances-ela026-in-pivotal-trial-for-rare-blood-disorder-shlh 2025-12-03T06:24:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/electra-therapeutics-advances-ela026-in-pivotal-trial-for-rare-blood-disorder-shlh 2025-12-03T06:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-to-reduce-primate-testing-for-monoclonal-antibody-therapies 2025-12-03T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-to-reduce-primate-testing-for-monoclonal-antibody-therapies 2025-12-03T06:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/antengene-receives-nmpa-approval-for-phase-ib-ii-study-of-atg-022-cldn18-2-adc-in-combination-with-pembrolizumab-for-gastric-cancer 2025-12-03T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antengene-receives-nmpa-approval-for-phase-ib-ii-study-of-atg-022-cldn18-2-adc-in-combination-with-pembrolizumab-for-gastric-cancer 2025-12-03T06:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/ajovy-becomes-first-cgrp-antagonist-approved-for-pediatric-migraine-prevention-following-positive-space-trial-results 2025-12-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ajovy-becomes-first-cgrp-antagonist-approved-for-pediatric-migraine-prevention-following-positive-space-trial-results 2025-12-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tang-capital-management-invests-56-8-million-in-celcuity-following-positive-phase-3-gedatolisib-results 2025-12-02T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tang-capital-management-invests-56-8-million-in-celcuity-following-positive-phase-3-gedatolisib-results 2025-12-02T22:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-initiates-phase-ii-trial-of-mrm-3379-for-fragile-x-syndrome 2025-12-02T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-initiates-phase-ii-trial-of-mrm-3379-for-fragile-x-syndrome 2025-12-02T15:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-index-test-shows-promise-for-identifying-low-risk-premenopausal-patients-who-may-avoid-aggressive-therapy 2025-12-02T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-index-test-shows-promise-for-identifying-low-risk-premenopausal-patients-who-may-avoid-aggressive-therapy 2025-12-02T13:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/bionexus-gene-lab-launches-vitaguard-mrd-platform-across-southeast-asia-to-challenge-3000-legacy-cancer-monitoring-systems 2025-12-02T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionexus-gene-lab-launches-vitaguard-mrd-platform-across-southeast-asia-to-challenge-3000-legacy-cancer-monitoring-systems 2025-12-02T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printed-corneal-implant-restores-sight-to-legally-blind-patient-in-world-first-surgery 2025-12-02T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-printed-corneal-implant-restores-sight-to-legally-blind-patient-in-world-first-surgery 2025-12-02T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurothera-labs-pursues-quantum-computing-acquisition-to-accelerate-cns-drug-development 2025-12-02T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurothera-labs-pursues-quantum-computing-acquisition-to-accelerate-cns-drug-development 2025-12-02T09:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-papillon-brachytherapy-for-nhs-use-in-early-stage-rectal-cancer 2025-12-02T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-papillon-brachytherapy-for-nhs-use-in-early-stage-rectal-cancer 2025-12-02T05:26:40+00:00 hourly 0.9 https://trial.medpath.com/news/lynk-pharmaceuticals-receives-fda-ind-approval-for-brain-penetrant-tyk2-inhibitor-lnk01006-targeting-neuroinflammatory-diseases 2025-12-02T05:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lynk-pharmaceuticals-receives-fda-ind-approval-for-brain-penetrant-tyk2-inhibitor-lnk01006-targeting-neuroinflammatory-diseases 2025-12-02T05:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/three-fda-approvals-in-three-months-transform-hereditary-angioedema-treatment-landscape-in-2025 2025-12-02T03:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-fda-approvals-in-three-months-transform-hereditary-angioedema-treatment-landscape-in-2025 2025-12-02T03:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-raises-350-million-to-advance-retinal-disease-therapies-toward-commercialization 2025-12-02T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-raises-350-million-to-advance-retinal-disease-therapies-toward-commercialization 2025-12-02T01:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/aptargroup-acquires-brazilian-oral-dosing-specialist-sommaplast-to-expand-pharmaceutical-packaging-capabilities 2025-12-01T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptargroup-acquires-brazilian-oral-dosing-specialist-sommaplast-to-expand-pharmaceutical-packaging-capabilities 2025-12-01T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/combination-immunotherapy-shows-promise-for-hiv-control-after-art-discontinuation 2025-12-01T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-immunotherapy-shows-promise-for-hiv-control-after-art-discontinuation 2025-12-01T21:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/apimeds-pharmaceuticals-merges-with-ai-driven-digital-asset-company-mindwave-in-100m-deal 2025-12-01T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apimeds-pharmaceuticals-merges-with-ai-driven-digital-asset-company-mindwave-in-100m-deal 2025-12-01T21:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/eib-and-angelini-ventures-launch-eur150-million-european-biotech-investment-initiative 2025-12-01T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eib-and-angelini-ventures-launch-eur150-million-european-biotech-investment-initiative 2025-12-01T21:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/juniper-biosciences-secures-40-million-seed-funding-to-advance-radiopharmaceutical-pipeline 2025-12-01T17:39:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juniper-biosciences-secures-40-million-seed-funding-to-advance-radiopharmaceutical-pipeline 2025-12-01T17:39:59+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-appoints-former-astrazeneca-executive-as-cfo-ahead-of-bexmarilimab-registrational-study 2025-12-01T17:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-pharmaceuticals-appoints-former-astrazeneca-executive-as-cfo-ahead-of-bexmarilimab-registrational-study 2025-12-01T17:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-secures-new-patent-for-kio-104-formulations-extending-market-protection-to-2043 2025-12-01T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-secures-new-patent-for-kio-104-formulations-extending-market-protection-to-2043 2025-12-01T17:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/salarius-pharmaceuticals-partners-with-texas-biomed-to-test-ai-designed-antiviral-against-h5n1-avian-flu 2025-12-01T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salarius-pharmaceuticals-partners-with-texas-biomed-to-test-ai-designed-antiviral-against-h5n1-avian-flu 2025-12-01T17:31:23+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-to-present-updated-clinical-data-from-phase-1b-2-trial-of-rec-4881-in-familial-adenomatous-polyposis 2025-12-01T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-to-present-updated-clinical-data-from-phase-1b-2-trial-of-rec-4881-in-familial-adenomatous-polyposis 2025-12-01T17:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/promis-neurosciences-validates-plasma-ptau-as-early-predictor-for-alzheimer-s-drug-development 2025-12-01T17:30:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promis-neurosciences-validates-plasma-ptau-as-early-predictor-for-alzheimer-s-drug-development 2025-12-01T17:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-s-neo100-shows-enhanced-brain-tumor-efficacy-when-combined-with-ultrasound-in-ai-driven-study 2025-12-01T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-s-neo100-shows-enhanced-brain-tumor-efficacy-when-combined-with-ultrasound-in-ai-driven-study 2025-12-01T17:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-partners-with-tessera-in-275m-gene-editing-deal-for-alpha-1-antitrypsin-deficiency-treatment 2025-12-01T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-partners-with-tessera-in-275m-gene-editing-deal-for-alpha-1-antitrypsin-deficiency-treatment 2025-12-01T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/akebia-therapeutics-establishes-rare-kidney-disease-pipeline-with-two-novel-therapeutic-candidates 2025-12-01T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akebia-therapeutics-establishes-rare-kidney-disease-pipeline-with-two-novel-therapeutic-candidates 2025-12-01T17:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/morphocell-technologies-completes-50-million-series-a-to-advance-liver-disease-therapeutics 2025-12-01T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morphocell-technologies-completes-50-million-series-a-to-advance-liver-disease-therapeutics 2025-12-01T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/keynote-811-trial-shows-pembrolizumab-combination-improves-response-rates-in-her2-positive-gastric-cancer 2025-12-01T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keynote-811-trial-shows-pembrolizumab-combination-improves-response-rates-in-her2-positive-gastric-cancer 2025-12-01T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/oncoprecision-s-first-in-class-cd64-targeting-adc-onc001-selected-for-oral-presentation-at-ash-2025 2025-12-01T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncoprecision-s-first-in-class-cd64-targeting-adc-onc001-selected-for-oral-presentation-at-ash-2025 2025-12-01T17:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-presents-long-term-data-supporting-belantamab-mafodotin-and-momelotinib-for-blood-cancers-at-ash-2024 2025-12-01T17:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-presents-long-term-data-supporting-belantamab-mafodotin-and-momelotinib-for-blood-cancers-at-ash-2024 2025-12-01T17:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-s-anti-st2-antibody-9mw1911-shows-over-40-reduction-in-severe-copd-exacerbations-in-phase-iia-trial 2025-12-01T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-s-anti-st2-antibody-9mw1911-shows-over-40-reduction-in-severe-copd-exacerbations-in-phase-iia-trial 2025-12-01T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/saga-diagnostics-presents-breakthrough-mrd-data-at-sabcs-2025-demonstrating-100-sensitivity-in-breast-cancer-detection 2025-12-01T17:24:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saga-diagnostics-presents-breakthrough-mrd-data-at-sabcs-2025-demonstrating-100-sensitivity-in-breast-cancer-detection 2025-12-01T17:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-secures-fda-rare-pediatric-disease-designation-for-novel-friedreich-s-ataxia-gene-therapy 2025-12-01T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-secures-fda-rare-pediatric-disease-designation-for-novel-friedreich-s-ataxia-gene-therapy 2025-12-01T17:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/merck-receives-fda-fast-track-designation-for-novel-alzheimer-s-tau-targeting-antibody-mk-2214 2025-12-01T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-receives-fda-fast-track-designation-for-novel-alzheimer-s-tau-targeting-antibody-mk-2214 2025-12-01T17:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-tazbentetol-as-international-name-for-spinogenix-s-first-in-class-synaptic-regenerative-therapy 2025-12-01T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-tazbentetol-as-international-name-for-spinogenix-s-first-in-class-synaptic-regenerative-therapy 2025-12-01T17:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-isopsa-blood-test-to-reduce-unnecessary-prostate-biopsies 2025-12-01T17:21:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-isopsa-blood-test-to-reduce-unnecessary-prostate-biopsies 2025-12-01T17:21:48+00:00 hourly 0.9 https://trial.medpath.com/news/jacobio-s-kras-g12c-combination-therapy-achieves-71-response-rate-in-first-line-nsclc-trial 2025-12-01T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jacobio-s-kras-g12c-combination-therapy-achieves-71-response-rate-in-first-line-nsclc-trial 2025-12-01T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/lenz-therapeutics-and-lotus-pharmaceutical-submit-vizz-for-presbyopia-treatment-approval-in-south-korea 2025-12-01T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenz-therapeutics-and-lotus-pharmaceutical-submit-vizz-for-presbyopia-treatment-approval-in-south-korea 2025-12-01T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-launches-five-year-real-world-trial-of-tirzepatide-in-uk-primary-care-settings 2025-12-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-launches-five-year-real-world-trial-of-tirzepatide-in-uk-primary-care-settings 2025-12-01T17:20:46+00:00 hourly 0.9 https://trial.medpath.com/news/glial-cell-immune-networks-drive-neuroinflammation-in-glaucomatous-optic-nerve-degeneration 2025-12-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glial-cell-immune-networks-drive-neuroinflammation-in-glaucomatous-optic-nerve-degeneration 2025-12-01T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridgebio-pharma-advances-three-potential-first-in-class-therapies-for-rare-diseases 2025-12-01T15:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridgebio-pharma-advances-three-potential-first-in-class-therapies-for-rare-diseases 2025-12-01T15:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-secures-major-cms-reimbursement-increase-for-genio-sleep-apnea-device 2025-12-01T14:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-secures-major-cms-reimbursement-increase-for-genio-sleep-apnea-device 2025-12-01T14:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-achieves-large-scale-gmp-manufacturing-milestone-for-vididencel-cell-therapy-in-aml-and-cml 2025-12-01T13:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mendus-achieves-large-scale-gmp-manufacturing-milestone-for-vididencel-cell-therapy-in-aml-and-cml 2025-12-01T13:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/protego-biopharma-raises-130m-to-advance-novel-protein-stabilization-approach-for-al-amyloidosis 2025-12-01T13:36:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protego-biopharma-raises-130m-to-advance-novel-protein-stabilization-approach-for-al-amyloidosis 2025-12-01T13:36:25+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-advances-oncology-pipeline-with-pivotal-tovecimig-data-expected-q1-2026 2025-12-01T13:35:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-advances-oncology-pipeline-with-pivotal-tovecimig-data-expected-q1-2026 2025-12-01T13:35:42+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-atogepant-shows-superior-efficacy-in-phase-3-eclipse-trial-for-acute-migraine-treatment 2025-12-01T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-atogepant-shows-superior-efficacy-in-phase-3-eclipse-trial-for-acute-migraine-treatment 2025-12-01T13:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/ideaya-biosciences-receives-fda-clearance-for-first-in-class-bispecific-adc-ide034-targeting-multiple-solid-tumors 2025-12-01T13:24:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ideaya-biosciences-receives-fda-clearance-for-first-in-class-bispecific-adc-ide034-targeting-multiple-solid-tumors 2025-12-01T13:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-shares-surge-19-following-fda-acceptance-of-zaynich-antibiotic-application 2025-12-01T13:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-shares-surge-19-following-fda-acceptance-of-zaynich-antibiotic-application 2025-12-01T13:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/zentiva-launches-first-biosimilar-monoclonal-antibody-across-eu-markets 2025-12-01T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zentiva-launches-first-biosimilar-monoclonal-antibody-across-eu-markets 2025-12-01T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/injectable-hiv-treatment-shows-promise-in-african-trial-offering-hope-for-improved-adherence 2025-12-01T09:25:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/injectable-hiv-treatment-shows-promise-in-african-trial-offering-hope-for-improved-adherence 2025-12-01T09:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/enlivex-therapeutics-secures-212-million-funding-for-osteoarthritis-therapy-development-and-digital-asset-strategy 2025-12-01T09:25:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enlivex-therapeutics-secures-212-million-funding-for-osteoarthritis-therapy-development-and-digital-asset-strategy 2025-12-01T09:25:23+00:00 hourly 0.9 https://trial.medpath.com/news/theia-ventures-leads-pre-seed-funding-for-lemnisca-s-ai-driven-biomanufacturing-platform 2025-12-01T09:25:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theia-ventures-leads-pre-seed-funding-for-lemnisca-s-ai-driven-biomanufacturing-platform 2025-12-01T09:25:11+00:00 hourly 0.9 https://trial.medpath.com/news/menin-inhibitors-show-promise-as-targeted-therapy-for-aggressive-kmt2a-rearranged-acute-leukemia 2025-12-01T09:23:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menin-inhibitors-show-promise-as-targeted-therapy-for-aggressive-kmt2a-rearranged-acute-leukemia 2025-12-01T09:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/australian-regulator-updates-safety-warnings-for-glp-1-drugs-over-suicidal-ideation-risk 2025-12-01T05:24:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-regulator-updates-safety-warnings-for-glp-1-drugs-over-suicidal-ideation-risk 2025-12-01T05:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/nitrous-oxide-shows-promise-as-rapid-acting-treatment-for-treatment-resistant-depression 2025-12-01T05:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nitrous-oxide-shows-promise-as-rapid-acting-treatment-for-treatment-resistant-depression 2025-12-01T05:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/nevada-health-centers-partners-with-javara-to-expand-clinical-trial-access-including-norovirus-vaccine-study 2025-12-01T05:22:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevada-health-centers-partners-with-javara-to-expand-clinical-trial-access-including-norovirus-vaccine-study 2025-12-01T05:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/zuellig-pharma-opens-advanced-clinical-trial-support-innovation-center-in-south-korea 2025-12-01T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zuellig-pharma-opens-advanced-clinical-trial-support-innovation-center-in-south-korea 2025-12-01T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/nanoviricides-submits-orphan-drug-application-for-nv-387-measles-treatment-as-cases-surge-in-us 2025-12-01T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanoviricides-submits-orphan-drug-application-for-nv-387-measles-treatment-as-cases-surge-in-us 2025-12-01T02:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-data-managers-lose-12-hours-weekly-to-manual-tasks-raising-quality-concerns 2025-12-01T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-data-managers-lose-12-hours-weekly-to-manual-tasks-raising-quality-concerns 2025-12-01T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-acquires-muse-endoscopy-patent-portfolio-to-enter-2-5-billion-gerd-device-market 2025-12-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-acquires-muse-endoscopy-patent-portfolio-to-enter-2-5-billion-gerd-device-market 2025-12-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avandra-health-acquires-datcard-systems-and-sorna-corporation-to-create-world-s-largest-medical-imaging-platform 2025-11-30T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avandra-health-acquires-datcard-systems-and-sorna-corporation-to-create-world-s-largest-medical-imaging-platform 2025-11-30T17:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/gut-brain-axis-emerges-as-key-pathway-in-parkinson-s-disease-pathogenesis 2025-11-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-brain-axis-emerges-as-key-pathway-in-parkinson-s-disease-pathogenesis 2025-11-30T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cereno-scientific-secures-sek-665-million-financing-to-advance-rare-disease-pipeline-through-2027 2025-11-30T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cereno-scientific-secures-sek-665-million-financing-to-advance-rare-disease-pipeline-through-2027 2025-11-30T13:22:14+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-s-niprd-and-futh-lafia-partner-to-advance-local-vaccine-and-drug-development 2025-11-30T05:21:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-s-niprd-and-futh-lafia-partner-to-advance-local-vaccine-and-drug-development 2025-11-30T05:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/ace2-decoy-receptor-shows-promise-against-multiple-sars-cov-2-variants-in-new-study 2025-11-29T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ace2-decoy-receptor-shows-promise-against-multiple-sars-cov-2-variants-in-new-study 2025-11-29T21:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/single-2-ml-mirikizumab-injection-demonstrates-bioequivalence-to-two-1-ml-doses-in-healthy-participants 2025-11-29T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-2-ml-mirikizumab-injection-demonstrates-bioequivalence-to-two-1-ml-doses-in-healthy-participants 2025-11-29T21:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/ultrasound-activated-nanocatalysts-trigger-novel-cancer-cell-death-mechanism-in-preclinical-study 2025-11-29T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultrasound-activated-nanocatalysts-trigger-novel-cancer-cell-death-mechanism-in-preclinical-study 2025-11-29T21:21:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-internal-memo-links-10-pediatric-deaths-to-covid-19-vaccination-citing-myocarditis-concerns 2025-11-29T14:25:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-internal-memo-links-10-pediatric-deaths-to-covid-19-vaccination-citing-myocarditis-concerns 2025-11-29T14:25:05+00:00 hourly 0.9 https://trial.medpath.com/news/zura-bio-advances-tibulizumab-phase-2-trials-with-139-million-cash-runway-through-2027 2025-11-29T14:24:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zura-bio-advances-tibulizumab-phase-2-trials-with-139-million-cash-runway-through-2027 2025-11-29T14:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hdac2-inhibitor-shows-promise-for-cancer-therapy-despite-acute-toxicity-concerns 2025-11-29T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hdac2-inhibitor-shows-promise-for-cancer-therapy-despite-acute-toxicity-concerns 2025-11-29T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/dea-finalizes-significant-increases-in-psychedelic-production-quotas-for-2026-to-support-ptsd-and-depression-research 2025-11-29T01:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dea-finalizes-significant-increases-in-psychedelic-production-quotas-for-2026-to-support-ptsd-and-depression-research 2025-11-29T01:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/terumo-bct-partners-with-santersus-to-advance-novel-blood-purification-technology-for-sepsis-treatment 2025-11-29T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/terumo-bct-partners-with-santersus-to-advance-novel-blood-purification-technology-for-sepsis-treatment 2025-11-29T01:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/australian-researchers-identify-romidepsin-as-breakthrough-treatment-for-relapsed-neuroblastoma 2025-11-29T01:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-researchers-identify-romidepsin-as-breakthrough-treatment-for-relapsed-neuroblastoma 2025-11-29T01:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/hanmi-pharmaceutical-s-hm16390-shows-dual-mechanism-for-enhanced-cancer-immunotherapy-safety-and-efficacy 2025-11-28T21:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanmi-pharmaceutical-s-hm16390-shows-dual-mechanism-for-enhanced-cancer-immunotherapy-safety-and-efficacy 2025-11-28T21:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-meta-analysis-confirms-galcanezumab-efficacy-in-migraine-prevention-across-3859-patients 2025-11-28T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-meta-analysis-confirms-galcanezumab-efficacy-in-migraine-prevention-across-3859-patients 2025-11-28T21:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-secures-60-million-funding-to-advance-mek-inhibitor-for-neurofibromatosis-treatment 2025-11-28T17:30:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-therapeutics-secures-60-million-funding-to-advance-mek-inhibitor-for-neurofibromatosis-treatment 2025-11-28T17:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-drug-agency-recommends-public-reimbursement-for-skyrizi-in-ulcerative-colitis 2025-11-28T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-drug-agency-recommends-public-reimbursement-for-skyrizi-in-ulcerative-colitis 2025-11-28T17:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-biopolymeric-nanocarrier-system-targets-cd44-receptors-for-enhanced-irinotecan-delivery-in-skin-cancer-treatment 2025-11-28T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-biopolymeric-nanocarrier-system-targets-cd44-receptors-for-enhanced-irinotecan-delivery-in-skin-cancer-treatment 2025-11-28T17:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-s-nasdaq-listing-back-on-track-after-us-government-shutdown-delays 2025-11-28T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veraxa-biotech-s-nasdaq-listing-back-on-track-after-us-government-shutdown-delays 2025-11-28T17:25:22+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-ce-mark-for-revolutionary-total-body-pet-ct-system-and-digital-spect-ct-platform 2025-11-28T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-receives-ce-mark-for-revolutionary-total-body-pet-ct-system-and-digital-spect-ct-platform 2025-11-28T17:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/cytiva-and-veeda-lifesciences-establish-host-cell-protein-analysis-center-in-india-to-support-biopharmaceutical-development 2025-11-28T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytiva-and-veeda-lifesciences-establish-host-cell-protein-analysis-center-in-india-to-support-biopharmaceutical-development 2025-11-28T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-first-dual-indication-car-t-therapy-receives-nmpa-approval-for-large-b-cell-lymphoma 2025-11-28T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-first-dual-indication-car-t-therapy-receives-nmpa-approval-for-large-b-cell-lymphoma 2025-11-28T17:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/profound-medical-launches-ai-powered-bph-module-and-expands-global-reach-through-strategic-partnerships 2025-11-28T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/profound-medical-launches-ai-powered-bph-module-and-expands-global-reach-through-strategic-partnerships 2025-11-28T17:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/ephb4-targeted-car-t-cell-therapy-enters-phase-i-trial-for-solid-tumors 2025-11-28T13:27:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ephb4-targeted-car-t-cell-therapy-enters-phase-i-trial-for-solid-tumors 2025-11-28T13:27:27+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-engineer-mrna-modified-allogeneic-mscs-for-enhanced-t-cell-immunotherapy 2025-11-28T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-engineer-mrna-modified-allogeneic-mscs-for-enhanced-t-cell-immunotherapy 2025-11-28T13:25:43+00:00 hourly 0.9 https://trial.medpath.com/news/lmu-researchers-develop-ai-powered-platform-to-accelerate-rna-drug-carrier-design 2025-11-28T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lmu-researchers-develop-ai-powered-platform-to-accelerate-rna-drug-carrier-design 2025-11-28T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-launches-ai-powered-spot-mas-multi-cancer-screening-platform-in-taiwan 2025-11-28T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-launches-ai-powered-spot-mas-multi-cancer-screening-platform-in-taiwan 2025-11-28T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-domestic-il-23p19-antibody-for-psoriasis-treatment 2025-11-28T13:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-domestic-il-23p19-antibody-for-psoriasis-treatment 2025-11-28T13:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-initiates-global-phase-ii-trial-of-tyk2-inhibitor-soficitinib-for-prurigo-nodularis-treatment 2025-11-28T09:22:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-initiates-global-phase-ii-trial-of-tyk2-inhibitor-soficitinib-for-prurigo-nodularis-treatment 2025-11-28T09:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/pre-transplant-treg-expansion-therapy-shows-promise-for-reducing-gvhd-risk-in-blood-cancer-patients 2025-11-28T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pre-transplant-treg-expansion-therapy-shows-promise-for-reducing-gvhd-risk-in-blood-cancer-patients 2025-11-28T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/fzocus-1-trial-shows-fuzuloparib-maintenance-therapy-improves-survival-in-advanced-ovarian-cancer 2025-11-28T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fzocus-1-trial-shows-fuzuloparib-maintenance-therapy-improves-survival-in-advanced-ovarian-cancer 2025-11-28T01:24:17+00:00 hourly 0.9 https://trial.medpath.com/news/bone-metastasis-treatment-pipeline-shows-robust-development-with-10-companies-advancing-novel-therapies 2025-11-28T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-metastasis-treatment-pipeline-shows-robust-development-with-10-companies-advancing-novel-therapies 2025-11-28T01:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/ge-healthcare-receives-fda-authorization-for-ai-powered-3d-mammography-technology 2025-11-28T01:23:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ge-healthcare-receives-fda-authorization-for-ai-powered-3d-mammography-technology 2025-11-28T01:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/northwestern-researchers-develop-reengineered-hpv-vaccine-that-trains-t-cells-to-hunt-cancer 2025-11-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwestern-researchers-develop-reengineered-hpv-vaccine-that-trains-t-cells-to-hunt-cancer 2025-11-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/transgene-secures-eur105-million-to-advance-personalized-cancer-vaccine-platform 2025-11-27T21:24:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transgene-secures-eur105-million-to-advance-personalized-cancer-vaccine-platform 2025-11-27T21:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-demonstrate-cartilage-regeneration-through-gerozyme-inhibition-in-preclinical-studies 2025-11-27T21:22:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-demonstrate-cartilage-regeneration-through-gerozyme-inhibition-in-preclinical-studies 2025-11-27T21:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/mbx-biosciences-advances-toward-phase-3-trial-despite-major-investor-exit 2025-11-27T20:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbx-biosciences-advances-toward-phase-3-trial-despite-major-investor-exit 2025-11-27T20:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/maibe-and-leniobio-form-strategic-partnership-to-accelerate-ai-driven-monoclonal-antibody-discovery 2025-11-27T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maibe-and-leniobio-form-strategic-partnership-to-accelerate-ai-driven-monoclonal-antibody-discovery 2025-11-27T17:24:21+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-mrna-norovirus-vaccine-enters-phase-3-trial-at-newcastle-hospitals 2025-11-27T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-mrna-norovirus-vaccine-enters-phase-3-trial-at-newcastle-hospitals 2025-11-27T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/neuraxpharm-and-mjn-neuro-launch-ai-powered-wearable-device-for-early-epileptic-seizure-detection 2025-11-27T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuraxpharm-and-mjn-neuro-launch-ai-powered-wearable-device-for-early-epileptic-seizure-detection 2025-11-27T17:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-shows-promise-in-treating-immune-checkpoint-inhibitor-associated-myocarditis-and-myasthenia-gravis 2025-11-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efgartigimod-shows-promise-in-treating-immune-checkpoint-inhibitor-associated-myocarditis-and-myasthenia-gravis 2025-11-27T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/monthly-tezepelumab-injection-enables-severe-asthma-patients-to-discontinue-daily-steroids 2025-11-27T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/monthly-tezepelumab-injection-enables-severe-asthma-patients-to-discontinue-daily-steroids 2025-11-27T13:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/mendus-reports-positive-2-year-follow-up-data-for-vididencel-immunotherapy-in-high-risk-ovarian-cancer 2025-11-27T13:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mendus-reports-positive-2-year-follow-up-data-for-vididencel-immunotherapy-in-high-risk-ovarian-cancer 2025-11-27T13:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/patronus-biotech-secures-gates-foundation-grant-for-novel-multi-stage-malaria-vaccine-development 2025-11-27T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patronus-biotech-secures-gates-foundation-grant-for-novel-multi-stage-malaria-vaccine-development 2025-11-27T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-medivir-s-miv-711-orphan-drug-designation-for-osteogenesis-imperfecta-treatment 2025-11-27T13:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-medivir-s-miv-711-orphan-drug-designation-for-osteogenesis-imperfecta-treatment 2025-11-27T13:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-pharmaceuticals-launches-phase-3-trial-for-once-monthly-glp-1-receptor-agonist-bofanglutide 2025-11-27T13:24:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-launches-phase-3-trial-for-once-monthly-glp-1-receptor-agonist-bofanglutide 2025-11-27T13:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-orphan-drug-designation-to-kedrion-s-ceruloplasmin-treatment-for-rare-iron-metabolism-disorder 2025-11-27T13:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-orphan-drug-designation-to-kedrion-s-ceruloplasmin-treatment-for-rare-iron-metabolism-disorder 2025-11-27T13:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-withdraws-asbestos-testing-rule-for-talc-cosmetics-plans-revised-proposal 2025-11-27T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-withdraws-asbestos-testing-rule-for-talc-cosmetics-plans-revised-proposal 2025-11-27T13:23:06+00:00 hourly 0.9 https://trial.medpath.com/news/delphx-capital-markets-completes-c-112000-private-placement-to-support-structured-products-development 2025-11-27T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delphx-capital-markets-completes-c-112000-private-placement-to-support-structured-products-development 2025-11-27T13:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharmaceuticals-licenses-wt-7695-radiopharmaceutical-targeting-ca9-for-solid-tumors 2025-11-27T10:23:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharmaceuticals-licenses-wt-7695-radiopharmaceutical-targeting-ca9-for-solid-tumors 2025-11-27T10:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-backed-anti-aging-drug-for-dogs-targets-2026-launch-following-efficacy-approval 2025-11-27T08:24:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-backed-anti-aging-drug-for-dogs-targets-2026-launch-following-efficacy-approval 2025-11-27T08:24:22+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-developed-her2-targeting-adc-tqb2102-achieves-77-complete-response-rate-in-phase-ii-breast-cancer-trial 2025-11-27T08:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-developed-her2-targeting-adc-tqb2102-achieves-77-complete-response-rate-in-phase-ii-breast-cancer-trial 2025-11-27T08:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-approves-inavolisib-for-advanced-hr-positive-her2-negative-breast-cancer 2025-11-27T05:21:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-approves-inavolisib-for-advanced-hr-positive-her2-negative-breast-cancer 2025-11-27T05:21:43+00:00 hourly 0.9 https://trial.medpath.com/news/federal-r-d-budget-cuts-threaten-us-biomedical-innovation-leadership 2025-11-27T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-r-d-budget-cuts-threaten-us-biomedical-innovation-leadership 2025-11-27T03:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/heartbeam-pursues-multiple-regulatory-paths-after-fda-rejects-12-lead-ecg-synthesis-software-application 2025-11-27T01:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartbeam-pursues-multiple-regulatory-paths-after-fda-rejects-12-lead-ecg-synthesis-software-application 2025-11-27T01:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-zotiraciclib-for-idh-mutant-recurrent-high-grade-glioma 2025-11-27T01:29:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-zotiraciclib-for-idh-mutant-recurrent-high-grade-glioma 2025-11-27T01:29:02+00:00 hourly 0.9 https://trial.medpath.com/news/imugene-partners-with-jw-therapeutics-to-develop-first-in-class-car-t-combination-for-solid-tumors 2025-11-27T01:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imugene-partners-with-jw-therapeutics-to-develop-first-in-class-car-t-combination-for-solid-tumors 2025-11-27T01:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-soars-23-on-fda-approval-of-redemplo-for-rare-genetic-disease 2025-11-27T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-soars-23-on-fda-approval-of-redemplo-for-rare-genetic-disease 2025-11-27T01:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/zetagen-therapeutics-raises-12-9m-in-oversubscribed-series-b1-round-following-promising-phase-2a-results-for-breast-cancer-treatment 2025-11-27T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zetagen-therapeutics-raises-12-9m-in-oversubscribed-series-b1-round-following-promising-phase-2a-results-for-breast-cancer-treatment 2025-11-27T01:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/kinase-inhibitors-discovered-to-trigger-widespread-protein-degradation-beyond-traditional-inhibition 2025-11-27T01:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kinase-inhibitors-discovered-to-trigger-widespread-protein-degradation-beyond-traditional-inhibition 2025-11-27T01:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/engasertib-shows-promise-in-first-controlled-trial-for-hereditary-hemorrhagic-telangiectasia 2025-11-27T01:24:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engasertib-shows-promise-in-first-controlled-trial-for-hereditary-hemorrhagic-telangiectasia 2025-11-27T01:24:07+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-consolidates-french-operations-closes-nantes-facility-amid-regulatory-setbacks 2025-11-26T21:28:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-consolidates-french-operations-closes-nantes-facility-amid-regulatory-setbacks 2025-11-26T21:28:12+00:00 hourly 0.9 https://trial.medpath.com/news/missing-prkci-gene-enhances-immunotherapy-response-in-lung-adenocarcinoma-through-senescent-cell-activation 2025-11-26T21:25:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/missing-prkci-gene-enhances-immunotherapy-response-in-lung-adenocarcinoma-through-senescent-cell-activation 2025-11-26T21:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-achieves-full-regulatory-compliance-for-nitrosamine-impurities 2025-11-26T21:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-achieves-full-regulatory-compliance-for-nitrosamine-impurities 2025-11-26T21:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-achieves-fda-approval-for-rodemplo-reports-strong-financial-turnaround 2025-11-26T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-achieves-fda-approval-for-rodemplo-reports-strong-financial-turnaround 2025-11-26T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-secures-fourth-patent-for-non-hallucinogenic-neuroplastogenic-drug-candidates 2025-11-26T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-secures-fourth-patent-for-non-hallucinogenic-neuroplastogenic-drug-candidates 2025-11-26T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/mount-sinai-researchers-develop-novel-mrna-therapy-to-combat-antibiotic-resistant-bacterial-infections 2025-11-26T17:26:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mount-sinai-researchers-develop-novel-mrna-therapy-to-combat-antibiotic-resistant-bacterial-infections 2025-11-26T17:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/scisparc-acquires-musetm-endoscopy-patents-to-target-3-billion-gerd-device-market 2025-11-26T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scisparc-acquires-musetm-endoscopy-patents-to-target-3-billion-gerd-device-market 2025-11-26T17:25:47+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-royalty-completes-2-035-per-share-acquisition-of-mural-oncology 2025-11-26T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-royalty-completes-2-035-per-share-acquisition-of-mural-oncology 2025-11-26T17:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/tangram-therapeutics-advances-novel-rnai-therapy-tgm-312-to-clinical-trials-for-mash-treatment 2025-11-26T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tangram-therapeutics-advances-novel-rnai-therapy-tgm-312-to-clinical-trials-for-mash-treatment 2025-11-26T17:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/lighthouse-pharmaceuticals-secures-49-2m-nih-grant-for-novel-alzheimer-s-treatment-targeting-bacterial-driver 2025-11-26T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lighthouse-pharmaceuticals-secures-49-2m-nih-grant-for-novel-alzheimer-s-treatment-targeting-bacterial-driver 2025-11-26T17:24:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novartis-gene-therapy-itvisma-for-spinal-muscular-atrophy-in-older-patients 2025-11-26T17:23:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novartis-gene-therapy-itvisma-for-spinal-muscular-atrophy-in-older-patients 2025-11-26T17:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/clairity-myriad-genetics-and-magview-launch-first-integrated-ai-genetic-risk-platform-for-breast-cancer-screening 2025-11-26T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clairity-myriad-genetics-and-magview-launch-first-integrated-ai-genetic-risk-platform-for-breast-cancer-screening 2025-11-26T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/four-gene-signature-predicts-oxaliplatin-response-in-colorectal-cancer 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-gene-signature-predicts-oxaliplatin-response-in-colorectal-cancer 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-atopic-dermatitis-patients-often-excluded-from-clinical-trials-study-reveals-safety-differences 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-atopic-dermatitis-patients-often-excluded-from-clinical-trials-study-reveals-safety-differences 2025-11-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/zymfentra-shows-consistent-efficacy-across-crohn-s-disease-locations-in-post-hoc-analysis-of-liberty-cd-study 2025-11-26T13:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zymfentra-shows-consistent-efficacy-across-crohn-s-disease-locations-in-post-hoc-analysis-of-liberty-cd-study 2025-11-26T13:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-public-input-process-for-bsufa-iv-reauthorization-to-shape-biosimilar-regulatory-framework-through-2032 2025-11-26T09:22:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-public-input-process-for-bsufa-iv-reauthorization-to-shape-biosimilar-regulatory-framework-through-2032 2025-11-26T09:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma 2025-11-26T09:21:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-updated-label-for-unloxcyt-based-on-long-term-data-showing-improved-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma 2025-11-26T09:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-reaches-400-global-manufacturing-approvals-reinforcing-cdmo-leadership 2025-11-26T09:21:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-reaches-400-global-manufacturing-approvals-reinforcing-cdmo-leadership 2025-11-26T09:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-launches-world-s-first-nebulized-triple-therapy-for-copd-treatment 2025-11-26T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-launches-world-s-first-nebulized-triple-therapy-for-copd-treatment 2025-11-26T09:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/galux-secures-29-million-series-b-to-advance-ai-driven-protein-design-platform 2025-11-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galux-secures-29-million-series-b-to-advance-ai-driven-protein-design-platform 2025-11-26T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-initiates-voluntary-correction-for-3-million-freestyle-libre-3-glucose-sensors-following-false-low-reading-reports 2025-11-26T05:24:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-initiates-voluntary-correction-for-3-million-freestyle-libre-3-glucose-sensors-following-false-low-reading-reports 2025-11-26T05:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-donepezil-depot-injection-shows-promise-for-canine-cognitive-dysfunction-treatment 2025-11-26T05:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-donepezil-depot-injection-shows-promise-for-canine-cognitive-dysfunction-treatment 2025-11-26T05:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-pharmaceutical-and-biomy-partner-to-develop-ai-powered-cancer-pathology-diagnostic-support-programs 2025-11-26T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-pharmaceutical-and-biomy-partner-to-develop-ai-powered-cancer-pathology-diagnostic-support-programs 2025-11-26T05:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-extends-review-timeline-for-ascendis-pharma-s-achondroplasia-treatment-to-february-2026 2025-11-26T01:26:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-extends-review-timeline-for-ascendis-pharma-s-achondroplasia-treatment-to-february-2026 2025-11-26T01:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-port-delivery-system-with-ranibizumab-shows-promise-in-japanese-phase-i-ii-trial-for-retinal-diseases 2025-11-26T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-port-delivery-system-with-ranibizumab-shows-promise-in-japanese-phase-i-ii-trial-for-retinal-diseases 2025-11-26T01:23:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns 2025-11-26T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-reformulated-ranitidine-after-five-year-market-absence-due-to-carcinogen-concerns 2025-11-26T01:23:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-accelerated-approval-for-novel-iga-nephropathy-treatment-voyxact 2025-11-26T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-accelerated-approval-for-novel-iga-nephropathy-treatment-voyxact 2025-11-26T01:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-higher-than-expected-atrial-fibrillation-risk-with-mavacamten-in-hypertrophic-cardiomyopathy-patients 2025-11-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-higher-than-expected-atrial-fibrillation-risk-with-mavacamten-in-hypertrophic-cardiomyopathy-patients 2025-11-26T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-intravaginal-mrna-platform-delivers-enhanced-hiv-protection-through-localized-antibody-production 2025-11-25T21:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-intravaginal-mrna-platform-delivers-enhanced-hiv-protection-through-localized-antibody-production 2025-11-25T21:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/canada-s-1-5-billion-rare-disease-strategy-shows-early-success-with-nine-life-saving-treatments 2025-11-25T21:27:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-s-1-5-billion-rare-disease-strategy-shows-early-success-with-nine-life-saving-treatments 2025-11-25T21:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-restructures-swiss-operations-with-550-job-cuts-while-investing-80m-in-rna-therapy-production 2025-11-25T21:27:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-restructures-swiss-operations-with-550-job-cuts-while-investing-80m-in-rna-therapy-production 2025-11-25T21:27:16+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-acquires-sprint-bioscience-s-trex1-cancer-program-in-414-million-deal 2025-11-25T21:24:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-acquires-sprint-bioscience-s-trex1-cancer-program-in-414-million-deal 2025-11-25T21:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-biotechnology-acquires-liora-technologies-light-proton-therapy-system-for-cancer-treatment 2025-11-25T21:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-biotechnology-acquires-liora-technologies-light-proton-therapy-system-for-cancer-treatment 2025-11-25T21:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/apatinib-plus-chemotherapy-extends-progression-free-survival-in-advanced-osteosarcoma-phase-ii-trial 2025-11-25T21:24:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apatinib-plus-chemotherapy-extends-progression-free-survival-in-advanced-osteosarcoma-phase-ii-trial 2025-11-25T21:24:15+00:00 hourly 0.9 https://trial.medpath.com/news/ceribell-receives-fda-clearance-for-ai-powered-seizure-detection-in-neonates 2025-11-25T21:23:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ceribell-receives-fda-clearance-for-ai-powered-seizure-detection-in-neonates 2025-11-25T21:23:14+00:00 hourly 0.9 https://trial.medpath.com/news/zanidatamab-demonstrates-durable-responses-in-her2-positive-biliary-tract-cancer-earns-fda-accelerated-approval 2025-11-25T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zanidatamab-demonstrates-durable-responses-in-her2-positive-biliary-tract-cancer-earns-fda-accelerated-approval 2025-11-25T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/new-market-analysis-reveals-global-monkeypox-clinical-trial-landscape-and-strategic-investment-opportunities 2025-11-25T21:21:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-market-analysis-reveals-global-monkeypox-clinical-trial-landscape-and-strategic-investment-opportunities 2025-11-25T21:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/xenon-pharmaceuticals-to-present-long-term-azetukalner-data-at-aes-2025-highlighting-extended-seizure-freedom 2025-11-25T17:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenon-pharmaceuticals-to-present-long-term-azetukalner-data-at-aes-2025-highlighting-extended-seizure-freedom 2025-11-25T17:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-receives-fda-approval-for-enhanced-elevidys-gene-therapy-trial-in-non-ambulatory-duchenne-patients 2025-11-25T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-receives-fda-approval-for-enhanced-elevidys-gene-therapy-trial-in-non-ambulatory-duchenne-patients 2025-11-25T17:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/adalyon-appoints-former-novo-nordisk-director-as-ceo-to-advance-ai-powered-speech-biomarkers-for-clinical-trials 2025-11-25T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adalyon-appoints-former-novo-nordisk-director-as-ceo-to-advance-ai-powered-speech-biomarkers-for-clinical-trials 2025-11-25T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/innova-therapeutics-acquires-enci-therapeutics-to-advance-first-in-class-sfrp2-targeting-cancer-antibody 2025-11-25T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innova-therapeutics-acquires-enci-therapeutics-to-advance-first-in-class-sfrp2-targeting-cancer-antibody 2025-11-25T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/who-approves-international-name-for-os-therapies-osteosarcoma-immunotherapy-ahead-of-regulatory-submissions 2025-11-25T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-approves-international-name-for-os-therapies-osteosarcoma-immunotherapy-ahead-of-regulatory-submissions 2025-11-25T17:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-amycretin-shows-promising-phase-2-results-in-type-2-diabetes-advances-to-phase-3-trials 2025-11-25T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-amycretin-shows-promising-phase-2-results-in-type-2-diabetes-advances-to-phase-3-trials 2025-11-25T17:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/caring-cross-partners-with-amrita-research-center-to-develop-affordable-car-t-and-gene-therapies-for-underserved-indian-populations 2025-11-25T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caring-cross-partners-with-amrita-research-center-to-develop-affordable-car-t-and-gene-therapies-for-underserved-indian-populations 2025-11-25T17:26:29+00:00 hourly 0.9 https://trial.medpath.com/news/tyrosine-kinase-inhibitors-and-gene-therapies-show-promise-for-wet-amd-treatment 2025-11-25T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyrosine-kinase-inhibitors-and-gene-therapies-show-promise-for-wet-amd-treatment 2025-11-25T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-max-3tm-syringeless-mri-injector-for-use-with-vueway-r-imaging-bulk-package 2025-11-25T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-max-3tm-syringeless-mri-injector-for-use-with-vueway-r-imaging-bulk-package 2025-11-25T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/precisionlife-and-ovation-partner-to-develop-precision-medicine-test-for-glp-1-drug-reimbursement 2025-11-25T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precisionlife-and-ovation-partner-to-develop-precision-medicine-test-for-glp-1-drug-reimbursement 2025-11-25T17:23:45+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-s-trop2-targeted-adc-shows-promise-in-first-line-lung-cancer-trial 2025-11-25T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-s-trop2-targeted-adc-shows-promise-in-first-line-lung-cancer-trial 2025-11-25T17:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-therapeutics-receives-1-million-als-association-grant-to-advance-pas-004-mek-inhibitor-in-phase-1-als-trial 2025-11-25T13:26:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-therapeutics-receives-1-million-als-association-grant-to-advance-pas-004-mek-inhibitor-in-phase-1-als-trial 2025-11-25T13:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-aucatzyl-car-t-therapy-for-adult-relapsed-refractory-b-cell-all-in-england-and-wales 2025-11-25T13:25:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-aucatzyl-car-t-therapy-for-adult-relapsed-refractory-b-cell-all-in-england-and-wales 2025-11-25T13:25:42+00:00 hourly 0.9 https://trial.medpath.com/news/active-biotech-secures-us-patent-for-tasquinimod-formulation-extending-market-exclusivity-to-2042 2025-11-25T13:24:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/active-biotech-secures-us-patent-for-tasquinimod-formulation-extending-market-exclusivity-to-2042 2025-11-25T13:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-abbvie-launch-neuroscience-collaboration-to-target-anhedonia-mechanisms 2025-11-25T09:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-abbvie-launch-neuroscience-collaboration-to-target-anhedonia-mechanisms 2025-11-25T09:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-launch-intelligence-transforms-pharmaceutical-market-entry-strategy 2025-11-25T07:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-launch-intelligence-transforms-pharmaceutical-market-entry-strategy 2025-11-25T07:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-approves-dupixent-as-first-line-targeted-therapy-for-chronic-spontaneous-urticaria 2025-11-25T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-approves-dupixent-as-first-line-targeted-therapy-for-chronic-spontaneous-urticaria 2025-11-25T06:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/ascentage-pharma-s-olverembatinib-shows-23-1-response-rate-in-rare-gist-subtype-with-novel-lipid-metabolism-mechanism 2025-11-25T05:26:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascentage-pharma-s-olverembatinib-shows-23-1-response-rate-in-rare-gist-subtype-with-novel-lipid-metabolism-mechanism 2025-11-25T05:26:22+00:00 hourly 0.9 https://trial.medpath.com/news/verrica-pharmaceuticals-secures-50-million-financing-to-advance-dermatology-pipeline-and-eliminate-debt 2025-11-25T05:26:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verrica-pharmaceuticals-secures-50-million-financing-to-advance-dermatology-pipeline-and-eliminate-debt 2025-11-25T05:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-submits-fda-application-for-first-in-class-adhd-drug-centanafadine 2025-11-25T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-submits-fda-application-for-first-in-class-adhd-drug-centanafadine 2025-11-25T05:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/nhs-approves-breakthrough-car-t-therapy-obe-cel-for-aggressive-leukemia-with-77-remission-rate 2025-11-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhs-approves-breakthrough-car-t-therapy-obe-cel-for-aggressive-leukemia-with-77-remission-rate 2025-11-25T05:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-discontinuation-before-pregnancy-linked-to-increased-weight-gain-and-complications 2025-11-25T01:28:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-discontinuation-before-pregnancy-linked-to-increased-weight-gain-and-complications 2025-11-25T01:28:54+00:00 hourly 0.9 https://trial.medpath.com/news/overweight-multiple-myeloma-patients-show-worse-outcomes-with-anti-bcma-car-t-therapy-in-u-shaped-bmi-pattern 2025-11-25T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/overweight-multiple-myeloma-patients-show-worse-outcomes-with-anti-bcma-car-t-therapy-in-u-shaped-bmi-pattern 2025-11-25T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/calcium-activated-switch-enhances-antibody-drug-conjugate-delivery-and-potency-in-cancer-treatment 2025-11-25T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcium-activated-switch-enhances-antibody-drug-conjugate-delivery-and-potency-in-cancer-treatment 2025-11-25T01:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-to-showcase-epilepsy-pipeline-at-aes-2025-with-full-radiant-study-results 2025-11-25T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-to-showcase-epilepsy-pipeline-at-aes-2025-with-full-radiant-study-results 2025-11-25T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/artera-s-ai-model-shows-promise-for-personalizing-breast-cancer-treatment-decisions 2025-11-25T01:24:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artera-s-ai-model-shows-promise-for-personalizing-breast-cancer-treatment-decisions 2025-11-25T01:24:30+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-receives-european-commission-approval-for-breyanzi-in-relapsed-refractory-mantle-cell-lymphoma 2025-11-25T01:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-receives-european-commission-approval-for-breyanzi-in-relapsed-refractory-mantle-cell-lymphoma 2025-11-25T01:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-intrathecal-gene-therapy-for-spinal-muscular-atrophy-across-all-ages 2025-11-25T01:23:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-intrathecal-gene-therapy-for-spinal-muscular-atrophy-across-all-ages 2025-11-25T01:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/aidoc-achieves-fda-clearance-for-healthcare-s-first-comprehensive-foundation-model-ai-triage-solution 2025-11-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aidoc-achieves-fda-clearance-for-healthcare-s-first-comprehensive-foundation-model-ai-triage-solution 2025-11-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-opens-advanced-therapies-collaboration-center-in-philadelphia-to-accelerate-cell-and-gene-therapy-development 2025-11-24T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-opens-advanced-therapies-collaboration-center-in-philadelphia-to-accelerate-cell-and-gene-therapy-development 2025-11-24T22:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/enquyst-technologies-achieves-breakthrough-in-monoclonal-antibody-manufacturing-with-chromatography-free-purification-platform 2025-11-24T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enquyst-technologies-achieves-breakthrough-in-monoclonal-antibody-manufacturing-with-chromatography-free-purification-platform 2025-11-24T21:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/kelonia-s-in-vivo-car-t-therapy-shows-promising-early-results-in-multiple-myeloma-patients 2025-11-24T21:25:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelonia-s-in-vivo-car-t-therapy-shows-promising-early-results-in-multiple-myeloma-patients 2025-11-24T21:25:19+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-receives-6-7-million-grant-to-expand-groundbreaking-kidney-transplant-trial-that-eliminates-immunosuppressive-drugs 2025-11-24T21:21:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-receives-6-7-million-grant-to-expand-groundbreaking-kidney-transplant-trial-that-eliminates-immunosuppressive-drugs 2025-11-24T21:21:26+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-clonoseq-mrd-test-featured-in-record-89-abstracts-at-ash-2025 2025-11-24T17:41:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-clonoseq-mrd-test-featured-in-record-89-abstracts-at-ash-2025 2025-11-24T17:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-reports-three-year-ojemda-data-shows-sustained-treatment-free-periods-in-pediatric-brain-cancer 2025-11-24T17:41:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-reports-three-year-ojemda-data-shows-sustained-treatment-free-periods-in-pediatric-brain-cancer 2025-11-24T17:41:13+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-therapeutics-advances-exosome-drug-delivery-with-scalable-manufacturing-framework 2025-11-24T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-therapeutics-advances-exosome-drug-delivery-with-scalable-manufacturing-framework 2025-11-24T17:39:28+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-presents-breakthrough-findings-in-blood-cancer-treatment-at-ash-2025 2025-11-24T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-presents-breakthrough-findings-in-blood-cancer-treatment-at-ash-2025 2025-11-24T17:38:14+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-group-to-present-new-elzonris-data-at-ash-2025-including-promising-triplet-therapy-results-for-bpdcn 2025-11-24T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menarini-group-to-present-new-elzonris-data-at-ash-2025-including-promising-triplet-therapy-results-for-bpdcn 2025-11-24T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/harmony-biosciences-reports-positive-bioequivalence-results-for-pitolisant-gr-formulation-plans-2026-nda-submission 2025-11-24T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmony-biosciences-reports-positive-bioequivalence-results-for-pitolisant-gr-formulation-plans-2026-nda-submission 2025-11-24T17:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-selects-vby329-as-potential-best-in-class-rsv-antibody-for-pediatric-prevention 2025-11-24T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-selects-vby329-as-potential-best-in-class-rsv-antibody-for-pediatric-prevention 2025-11-24T17:34:52+00:00 hourly 0.9 https://trial.medpath.com/news/adia-nutrition-submits-patent-pending-autism-protocol-for-irb-review-advancing-stem-cell-therapy-study 2025-11-24T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adia-nutrition-submits-patent-pending-autism-protocol-for-irb-review-advancing-stem-cell-therapy-study 2025-11-24T17:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/vertero-therapeutics-launches-phase-1-trial-of-vt-5006-first-in-class-gut-selective-therapy-for-parkinson-s-disease 2025-11-24T17:31:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertero-therapeutics-launches-phase-1-trial-of-vt-5006-first-in-class-gut-selective-therapy-for-parkinson-s-disease 2025-11-24T17:31:18+00:00 hourly 0.9 https://trial.medpath.com/news/amorphical-enrolls-first-patient-in-phase-2-trial-testing-novel-nano-amorphous-mineral-therapy-for-stage-iv-pancreatic-cancer 2025-11-24T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amorphical-enrolls-first-patient-in-phase-2-trial-testing-novel-nano-amorphous-mineral-therapy-for-stage-iv-pancreatic-cancer 2025-11-24T17:31:12+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-therapeutics-plans-phase-3-trial-for-next-generation-cystinosis-treatment-tti-0102 2025-11-24T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thiogenesis-therapeutics-plans-phase-3-trial-for-next-generation-cystinosis-treatment-tti-0102 2025-11-24T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/jyong-biotech-signs-letter-of-intent-for-mcs-2-licensing-in-south-korea 2025-11-24T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jyong-biotech-signs-letter-of-intent-for-mcs-2-licensing-in-south-korea 2025-11-24T17:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/can-fite-seeks-veterinary-partnerships-for-cancer-drug-namodenoson-at-biofit-2025 2025-11-24T17:27:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/can-fite-seeks-veterinary-partnerships-for-cancer-drug-namodenoson-at-biofit-2025 2025-11-24T17:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-appoints-dr-dongzhou-jeffery-liu-as-new-ceo-amid-leadership-transition 2025-11-24T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-appoints-dr-dongzhou-jeffery-liu-as-new-ceo-amid-leadership-transition 2025-11-24T17:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-partners-with-dayra-therapeutics-in-50-million-deal-to-develop-oral-macrocyclic-peptides-for-immunological-conditions 2025-11-24T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-partners-with-dayra-therapeutics-in-50-million-deal-to-develop-oral-macrocyclic-peptides-for-immunological-conditions 2025-11-24T17:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/oral-semaglutide-fails-to-slow-alzheimer-s-disease-progression-in-phase-3-trials 2025-11-24T17:26:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-semaglutide-fails-to-slow-alzheimer-s-disease-progression-in-phase-3-trials 2025-11-24T17:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/in-vivo-car-t-therapies-drive-6-1-billion-in-biotech-acquisitions-as-investors-shift-from-traditional-cell-therapy-approaches 2025-11-24T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-vivo-car-t-therapies-drive-6-1-billion-in-biotech-acquisitions-as-investors-shift-from-traditional-cell-therapy-approaches 2025-11-24T17:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-cladribine-capsules-receive-fda-fast-track-designation-for-rare-neuromuscular-disorder 2025-11-24T17:26:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-cladribine-capsules-receive-fda-fast-track-designation-for-rare-neuromuscular-disorder 2025-11-24T17:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/ocular-therapeutix-initiates-helios-3-phase-3-trial-for-axpaxli-in-diabetic-retinopathy 2025-11-24T17:25:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocular-therapeutix-initiates-helios-3-phase-3-trial-for-axpaxli-in-diabetic-retinopathy 2025-11-24T17:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-3-essential-thrombocythemia-trial 2025-11-24T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ropeginterferon-alfa-2b-shows-superior-efficacy-over-anagrelide-in-phase-3-essential-thrombocythemia-trial 2025-11-24T17:24:40+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-s-posdinemab-fails-phase-2b-trial-dealing-blow-to-tau-targeting-alzheimer-s-therapies 2025-11-24T17:23:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-s-posdinemab-fails-phase-2b-trial-dealing-blow-to-tau-targeting-alzheimer-s-therapies 2025-11-24T17:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-unveils-blood-based-circular-rna-biomarkers-for-early-alzheimer-s-disease-detection 2025-11-24T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-genomics-unveils-blood-based-circular-rna-biomarkers-for-early-alzheimer-s-disease-detection 2025-11-24T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/versant-ventures-launches-dayra-therapeutics-with-70m-funding-and-biogen-partnership-for-oral-macrocyclic-peptides 2025-11-24T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/versant-ventures-launches-dayra-therapeutics-with-70m-funding-and-biogen-partnership-for-oral-macrocyclic-peptides 2025-11-24T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-receives-fda-clearance-for-pivotal-phase-3-trial-of-primec-in-als 2025-11-24T17:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-receives-fda-clearance-for-pivotal-phase-3-trial-of-primec-in-als 2025-11-24T17:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-associated-macrophages-drive-gastric-cancer-progression-through-immune-evasion-and-therapeutic-resistance 2025-11-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-associated-macrophages-drive-gastric-cancer-progression-through-immune-evasion-and-therapeutic-resistance 2025-11-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/century-old-diabetes-drug-metformin-reduces-insulin-requirements-in-type-1-diabetes-patients 2025-11-24T13:25:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-old-diabetes-drug-metformin-reduces-insulin-requirements-in-type-1-diabetes-patients 2025-11-24T13:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-technology-shows-promise-for-preventing-muscle-damage-from-snakebites 2025-11-24T13:25:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-technology-shows-promise-for-preventing-muscle-damage-from-snakebites 2025-11-24T13:25:02+00:00 hourly 0.9 https://trial.medpath.com/news/vaximm-secures-potential-835m-deal-with-bcm-europe-for-oral-cancer-immunotherapy-platform-vxm01 2025-11-24T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaximm-secures-potential-835m-deal-with-bcm-europe-for-oral-cancer-immunotherapy-platform-vxm01 2025-11-24T13:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/genenta-science-reports-sustained-survival-benefits-in-glioblastoma-trial-with-temferon-cell-therapy 2025-11-24T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genenta-science-reports-sustained-survival-benefits-in-glioblastoma-trial-with-temferon-cell-therapy 2025-11-24T13:24:03+00:00 hourly 0.9 https://trial.medpath.com/news/pin-therapeutics-begins-first-in-human-trial-of-ck1a-degrader-pin-5018-for-rare-adenoid-cystic-carcinoma 2025-11-24T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pin-therapeutics-begins-first-in-human-trial-of-ck1a-degrader-pin-5018-for-rare-adenoid-cystic-carcinoma 2025-11-24T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/ananda-pharma-exits-public-markets-and-nhs-epilepsy-trial-to-focus-on-pain-treatment-pipeline 2025-11-24T13:23:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ananda-pharma-exits-public-markets-and-nhs-epilepsy-trial-to-focus-on-pain-treatment-pipeline 2025-11-24T13:23:37+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-to-acquire-exact-sciences-for-21-billion-in-major-cancer-diagnostics-consolidation 2025-11-24T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-laboratories-to-acquire-exact-sciences-for-21-billion-in-major-cancer-diagnostics-consolidation 2025-11-24T13:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/sequana-medical-achieves-first-u-s-commercial-implantation-of-alfapump-r-system-at-mount-sinai-hospital 2025-11-24T13:22:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequana-medical-achieves-first-u-s-commercial-implantation-of-alfapump-r-system-at-mount-sinai-hospital 2025-11-24T13:22:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-cleared-ai-platform-somnum-reduces-sleep-clinical-trial-timelines-by-50 2025-11-24T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-cleared-ai-platform-somnum-reduces-sleep-clinical-trial-timelines-by-50 2025-11-24T13:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/biocortex-partners-with-cd-biopharma-to-accelerate-precision-immunotherapy-development-using-ai-driven-platform 2025-11-24T13:22:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocortex-partners-with-cd-biopharma-to-accelerate-precision-immunotherapy-development-using-ai-driven-platform 2025-11-24T13:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/dexamethasone-shows-promise-against-therapy-resistant-breast-cancer-metastases-in-preclinical-studies 2025-11-24T13:21:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexamethasone-shows-promise-against-therapy-resistant-breast-cancer-metastases-in-preclinical-studies 2025-11-24T13:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-biologics-completes-strategic-spinoff-to-enhance-biosimilar-and-novel-drug-development 2025-11-24T09:22:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-biologics-completes-strategic-spinoff-to-enhance-biosimilar-and-novel-drug-development 2025-11-24T09:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/austrian-multicenter-study-demonstrates-hifu-as-effective-organ-preserving-treatment-for-early-prostate-cancer 2025-11-24T09:22:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/austrian-multicenter-study-demonstrates-hifu-as-effective-organ-preserving-treatment-for-early-prostate-cancer 2025-11-24T09:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-regulatory-reversals-disrupt-drug-development-timelines-for-uniqure-biohaven-and-capricor 2025-11-24T09:21:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-regulatory-reversals-disrupt-drug-development-timelines-for-uniqure-biohaven-and-capricor 2025-11-24T09:21:32+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-biotech-sector-emerges-as-key-player-as-big-pharma-faces-300-billion-patent-cliff-through-2030 2025-11-24T08:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-biotech-sector-emerges-as-key-player-as-big-pharma-faces-300-billion-patent-cliff-through-2030 2025-11-24T08:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-across-multiple-development-phases 2025-11-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-negative-breast-cancer-pipeline-expands-with-170-emerging-therapies-across-multiple-development-phases 2025-11-24T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-gene-therapy-shows-remarkable-success-in-three-year-old-with-hunter-syndrome 2025-11-24T05:21:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-gene-therapy-shows-remarkable-success-in-three-year-old-with-hunter-syndrome 2025-11-24T05:21:49+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-expands-astrazeneca-partnership-for-next-generation-oncology-therapeutics 2025-11-24T05:21:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-expands-astrazeneca-partnership-for-next-generation-oncology-therapeutics 2025-11-24T05:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/geneditbio-and-toolgen-form-strategic-alliance-to-advance-crispr-based-cardiovascular-gene-therapy 2025-11-24T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geneditbio-and-toolgen-form-strategic-alliance-to-advance-crispr-based-cardiovascular-gene-therapy 2025-11-24T05:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/hpv-vaccination-shows-dramatic-80-reduction-in-cervical-cancer-risk-when-given-before-age-16 2025-11-24T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hpv-vaccination-shows-dramatic-80-reduction-in-cervical-cancer-risk-when-given-before-age-16 2025-11-24T04:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-presents-ai-discovered-cns-penetrant-atr-mtor-dual-inhibitors-at-neuro-oncology-meeting 2025-11-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakovina-therapeutics-presents-ai-discovered-cns-penetrant-atr-mtor-dual-inhibitors-at-neuro-oncology-meeting 2025-11-24T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-asundexian-shows-promise-in-phase-iii-stroke-prevention-trial-after-2023-setback 2025-11-23T21:22:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-asundexian-shows-promise-in-phase-iii-stroke-prevention-trial-after-2023-setback 2025-11-23T21:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/black-cumin-seed-shows-promise-for-cholesterol-management-and-fat-cell-inhibition-in-clinical-trial 2025-11-23T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-cumin-seed-shows-promise-for-cholesterol-management-and-fat-cell-inhibition-in-clinical-trial 2025-11-23T17:20:09+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-t-cell-therapies-advance-through-clinical-development-with-enhanced-monitoring-technologies 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-t-cell-therapies-advance-through-clinical-development-with-enhanced-monitoring-technologies 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bacteriophage-yz2-shows-promise-against-carbapenem-resistant-acinetobacter-baumannii-in-combination-therapy 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bacteriophage-yz2-shows-promise-against-carbapenem-resistant-acinetobacter-baumannii-in-combination-therapy 2025-11-23T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/innocan-pharma-s-cbd-delivery-platform-achieves-28-day-sustained-release-in-regulatory-study 2025-11-23T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocan-pharma-s-cbd-delivery-platform-achieves-28-day-sustained-release-in-regulatory-study 2025-11-23T13:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/trikafta-shows-sustained-anti-inflammatory-effects-in-cystic-fibrosis-patients-through-2-5-years 2025-11-23T09:22:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trikafta-shows-sustained-anti-inflammatory-effects-in-cystic-fibrosis-patients-through-2-5-years 2025-11-23T09:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/gho-capital-partners-acquires-ai-powered-r-d-platform-scientist-com-to-accelerate-pharmaceutical-research-efficiency 2025-11-23T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gho-capital-partners-acquires-ai-powered-r-d-platform-scientist-com-to-accelerate-pharmaceutical-research-efficiency 2025-11-23T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/erdafitinib-shows-promising-early-efficacy-and-manageable-safety-profile-in-fgfr-tacc-fusion-positive-glioma 2025-11-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/erdafitinib-shows-promising-early-efficacy-and-manageable-safety-profile-in-fgfr-tacc-fusion-positive-glioma 2025-11-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-eight-fda-observations-following-ten-day-inspection-at-jadcherla-manufacturing-facility 2025-11-23T05:20:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-receives-eight-fda-observations-following-ten-day-inspection-at-jadcherla-manufacturing-facility 2025-11-23T05:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-drug-chief-pazdur-challenges-commissioner-s-expedited-approval-plans 2025-11-23T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-new-drug-chief-pazdur-challenges-commissioner-s-expedited-approval-plans 2025-11-23T01:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-trial-shows-safety-of-intraventricular-her2-car-t-therapy-for-brain-metastases-in-breast-cancer 2025-11-23T01:23:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-trial-shows-safety-of-intraventricular-her2-car-t-therapy-for-brain-metastases-in-breast-cancer 2025-11-23T01:23:09+00:00 hourly 0.9 https://trial.medpath.com/news/lutetium-lu-177-dotatate-demonstrates-significant-efficacy-in-advanced-intracranial-meningioma-phase-2-trial 2025-11-23T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lutetium-lu-177-dotatate-demonstrates-significant-efficacy-in-advanced-intracranial-meningioma-phase-2-trial 2025-11-23T01:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-identify-rna-molecule-that-may-reverse-als-nerve-damage-in-preclinical-studies 2025-11-23T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-identify-rna-molecule-that-may-reverse-als-nerve-damage-in-preclinical-studies 2025-11-23T01:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/oral-arginine-shows-promise-as-cost-effective-alzheimer-s-treatment-in-preclinical-studies 2025-11-22T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-arginine-shows-promise-as-cost-effective-alzheimer-s-treatment-in-preclinical-studies 2025-11-22T21:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/ajinomoto-partners-with-forge-biologics-to-double-gene-therapy-manufacturing-productivity 2025-11-22T21:23:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ajinomoto-partners-with-forge-biologics-to-double-gene-therapy-manufacturing-productivity 2025-11-22T21:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/cassandra-phase-3-trial-shows-paxg-superior-to-mfolfirinox-in-preoperative-pancreatic-cancer-treatment 2025-11-22T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cassandra-phase-3-trial-shows-paxg-superior-to-mfolfirinox-in-preoperative-pancreatic-cancer-treatment 2025-11-22T21:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-regoma-2-trial-establishes-safe-dosing-for-regorafenib-combination-in-mgmt-methylated-glioblastoma 2025-11-22T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-regoma-2-trial-establishes-safe-dosing-for-regorafenib-combination-in-mgmt-methylated-glioblastoma 2025-11-22T17:21:02+00:00 hourly 0.9 https://trial.medpath.com/news/uskudar-university-partners-with-sartorius-to-advance-gene-therapy-and-cell-based-treatment-manufacturing-in-turkey 2025-11-22T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uskudar-university-partners-with-sartorius-to-advance-gene-therapy-and-cell-based-treatment-manufacturing-in-turkey 2025-11-22T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/combicor-vax-phase-ii-trial-combines-dendritic-cell-vaccine-with-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2025-11-22T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combicor-vax-phase-ii-trial-combines-dendritic-cell-vaccine-with-pembrolizumab-for-refractory-microsatellite-stable-metastatic-colorectal-cancer 2025-11-22T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/osr-holdings-subsidiary-vaximm-secures-835m-licensing-deal-for-oral-cancer-immunotherapy-vxm01 2025-11-22T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osr-holdings-subsidiary-vaximm-secures-835m-licensing-deal-for-oral-cancer-immunotherapy-vxm01 2025-11-22T09:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-cardiovascular-disease 2025-11-22T05:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-partners-with-repair-biotechnologies-to-develop-novel-mrna-therapy-for-cardiovascular-disease 2025-11-22T05:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-treatment-gap-in-idh-mutant-glioma-supporting-need-for-early-intervention 2025-11-22T05:21:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-treatment-gap-in-idh-mutant-glioma-supporting-need-for-early-intervention 2025-11-22T05:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/mirdametinib-achieves-87-response-rate-in-pediatric-low-grade-glioma-phase-1-2-trial 2025-11-22T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirdametinib-achieves-87-response-rate-in-pediatric-low-grade-glioma-phase-1-2-trial 2025-11-22T05:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-mirdametinib-data-shows-improved-response-rates-and-deeper-tumor-shrinkage-in-nf1-associated-plexiform-neurofibromas 2025-11-22T05:21:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-mirdametinib-data-shows-improved-response-rates-and-deeper-tumor-shrinkage-in-nf1-associated-plexiform-neurofibromas 2025-11-22T05:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/immune-checkpoint-inhibitors-show-promise-for-triple-negative-breast-cancer-despite-increased-toxicity-risks 2025-11-22T05:21:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immune-checkpoint-inhibitors-show-promise-for-triple-negative-breast-cancer-despite-increased-toxicity-risks 2025-11-22T05:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-advances-multiple-neurological-programs-following-essential-tremor-success 2025-11-22T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-advances-multiple-neurological-programs-following-essential-tremor-success 2025-11-22T05:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/aston-university-and-comvita-file-patent-for-enhanced-manuka-honey-formulation-against-drug-resistant-bacteria 2025-11-22T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aston-university-and-comvita-file-patent-for-enhanced-manuka-honey-formulation-against-drug-resistant-bacteria 2025-11-22T05:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-first-clinical-trial-of-puberty-blockers-following-government-ban 2025-11-22T05:19:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-first-clinical-trial-of-puberty-blockers-following-government-ban 2025-11-22T05:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-countermeasure-in-collaboration-with-canadian-defense-agency 2025-11-21T21:43:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revive-therapeutics-advances-bucillamine-research-for-nerve-agent-countermeasure-in-collaboration-with-canadian-defense-agency 2025-11-21T21:43:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-investigates-fatal-adverse-event-linked-to-takeda-s-adzynma-enzyme-replacement-therapy 2025-11-21T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-investigates-fatal-adverse-event-linked-to-takeda-s-adzynma-enzyme-replacement-therapy 2025-11-21T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/guselkumab-shows-superior-treatment-persistence-over-il-17a-inhibitors-in-psoriatic-arthritis-study 2025-11-21T21:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guselkumab-shows-superior-treatment-persistence-over-il-17a-inhibitors-in-psoriatic-arthritis-study 2025-11-21T21:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-commits-2-billion-to-expand-maryland-manufacturing-operations-doubling-biologics-capacity 2025-11-21T21:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-commits-2-billion-to-expand-maryland-manufacturing-operations-doubling-biologics-capacity 2025-11-21T21:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-anaptysbio-file-dueling-lawsuits-over-jemperli-royalty-agreement-as-cancer-drug-nears-blockbuster-status 2025-11-21T21:31:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-anaptysbio-file-dueling-lawsuits-over-jemperli-royalty-agreement-as-cancer-drug-nears-blockbuster-status 2025-11-21T21:31:42+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-cincinnati-leads-multicenter-trial-testing-extended-tranexamic-acid-for-acl-surgery-recovery 2025-11-21T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-cincinnati-leads-multicenter-trial-testing-extended-tranexamic-acid-for-acl-surgery-recovery 2025-11-21T21:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-cell-and-gene-therapy-cdmo-market-set-for-explosive-growth-projected-to-reach-10-34-billion-by-2033 2025-11-21T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-cell-and-gene-therapy-cdmo-market-set-for-explosive-growth-projected-to-reach-10-34-billion-by-2033 2025-11-21T17:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/five-year-juliet-trial-data-confirms-tisagenlecleucel-as-curative-car-t-therapy-for-relapsed-refractory-large-b-cell-lymphoma 2025-11-21T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-year-juliet-trial-data-confirms-tisagenlecleucel-as-curative-car-t-therapy-for-relapsed-refractory-large-b-cell-lymphoma 2025-11-21T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/polaryx-therapeutics-secures-nasdaq-listing-ahead-of-phase-2-trial-for-rare-lysosomal-storage-disorders 2025-11-21T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polaryx-therapeutics-secures-nasdaq-listing-ahead-of-phase-2-trial-for-rare-lysosomal-storage-disorders 2025-11-21T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-begins-construction-of-advanced-grade-c-manufacturing-suite-to-scale-dcvax-production 2025-11-21T17:22:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-begins-construction-of-advanced-grade-c-manufacturing-suite-to-scale-dcvax-production 2025-11-21T17:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/sorcero-raises-42-5m-series-b-to-scale-ai-platform-for-life-sciences-evidence-generation 2025-11-21T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sorcero-raises-42-5m-series-b-to-scale-ai-platform-for-life-sciences-evidence-generation 2025-11-21T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-blue-lake-s-pediatric-rsv-vaccine-trial-allowing-enrollment-of-rsv-negative-toddlers 2025-11-21T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-blue-lake-s-pediatric-rsv-vaccine-trial-allowing-enrollment-of-rsv-negative-toddlers 2025-11-21T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-alnylam-s-vutrisiran-for-nhs-use-in-rare-heart-condition-attr-cm 2025-11-21T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-alnylam-s-vutrisiran-for-nhs-use-in-rare-heart-condition-attr-cm 2025-11-21T17:22:01+00:00 hourly 0.9 https://trial.medpath.com/news/waltz-health-launches-industry-first-direct-to-employer-model-for-obesity-medications 2025-11-21T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waltz-health-launches-industry-first-direct-to-employer-model-for-obesity-medications 2025-11-21T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/evofem-s-phexx-advances-toward-uae-approval-as-first-hormone-free-contraceptive-gel 2025-11-21T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evofem-s-phexx-advances-toward-uae-approval-as-first-hormone-free-contraceptive-gel 2025-11-21T17:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-pipe-307-fails-phase-2-multiple-sclerosis-trial 2025-11-21T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-pipe-307-fails-phase-2-multiple-sclerosis-trial 2025-11-21T13:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/bioatla-secures-22-5-million-flexible-financing-to-support-operations-while-pursuing-strategic-partnership 2025-11-21T13:56:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioatla-secures-22-5-million-flexible-financing-to-support-operations-while-pursuing-strategic-partnership 2025-11-21T13:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/crossbridge-bio-secures-15-million-cprit-grant-to-advance-novel-dual-payload-adc-cbb-120-targeting-trop-2 2025-11-21T13:54:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crossbridge-bio-secures-15-million-cprit-grant-to-advance-novel-dual-payload-adc-cbb-120-targeting-trop-2 2025-11-21T13:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/meril-s-myval-transcatheter-heart-valve-shows-comparable-one-year-outcomes-to-leading-competitors-in-landmark-trial 2025-11-21T13:53:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meril-s-myval-transcatheter-heart-valve-shows-comparable-one-year-outcomes-to-leading-competitors-in-landmark-trial 2025-11-21T13:53:58+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-70-reduction-in-atherosclerotic-plaque-in-preclinical-study 2025-11-21T13:53:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-70-reduction-in-atherosclerotic-plaque-in-preclinical-study 2025-11-21T13:53:45+00:00 hourly 0.9 https://trial.medpath.com/news/dicot-pharma-s-lib-01-shows-sustained-erectile-dysfunction-treatment-effects-in-phase-2a-trial 2025-11-21T13:53:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dicot-pharma-s-lib-01-shows-sustained-erectile-dysfunction-treatment-effects-in-phase-2a-trial 2025-11-21T13:53:12+00:00 hourly 0.9